Rahul Mittal
Rebecca Goldmann1
Khemraj Hirani- 1Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, United States
- 2Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, United States
Type 1 diabetes (T1D) is an autoimmune disorder driven by progressive destruction of pancreatic β-cells under conditions of metabolic and oxidative stress. This article examines the intersection of immunometabolism and antigen presentation as a central mechanism in T1D pathogenesis. In β-cells, endoplasmic reticulum (ER) stress, mitochondrial dysfunction, and redox imbalance remodel the immunopeptidome, promoting neoepitope formation and upregulation of major histocompatibility complex class I (MHC-I) molecules. Concurrently, antigen-presenting cells (APCs) exposed to hypoxia, cytokines, and nutrient deprivation undergo metabolic reprogramming that enhances glycolysis, reactive oxygen species (ROS) production, and pro-inflammatory antigen processing. These parallel responses establish a self-sustaining β-cell–APC loop in which metabolic distress in one cell type amplifies dysfunction in the other. By integrating evidence from redox signaling, immunopeptidomics, and metabolic regulation, this perspective defines a unified framework wherein metabolism acts as both initiator and amplifier of autoimmunity. Targeting the immunometabolic interface between β-cells and APCs may restore immune tolerance and prevent disease progression by re-establishing cellular homeostasis.
1 Introduction
Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by the targeted destruction of insulin-producing β-cells within the pancreatic islets (1–5). Classically, this process has been attributed to autoreactive cytotoxic CD8+ T lymphocytes that recognize β-cell–derived peptides presented by major histocompatibility complex class I (MHC-I) molecules (6). Although immune cells are the immediate effectors of β-cell death, increasing evidence suggests that β-cells themselves are active participants in the autoimmune process (7, 8). Rather than being inert targets, they exhibit a dynamic stress response to metabolic, inflammatory, and viral stimuli that profoundly alters their phenotype and immunogenicity (9).
1.1 β-Cells as active participants in autoimmune initiation
Under conditions of metabolic or inflammatory stress, β-cells activate adaptive pathways that alter both cellular homeostasis and antigen presentation (10). The secretory burden of insulin biosynthesis renders β-cells especially vulnerable to endoplasmic reticulum (ER) stress, and their relatively limited antioxidant defense predisposes them to oxidative injury (11). These stress responses activate the unfolded-protein response (UPR), mitochondrial stress signaling, and redox-sensitive transcriptional programs that modify peptide processing and antigen presentation. As a result, the β-cell surface repertoire of MHC-bound peptides changes both qualitatively and quantitatively, generating neoepitopes that can be recognized by autoreactive T cells (Figure 1). Autoimmune diseases often arise when immune surveillance mechanisms begin to recognize previously hidden or structurally altered self-antigens (12).
Figure 1. Cellular stress–induced molecular modifications generating neoepitope classes in pancreatic β-cells. ER stress, oxidative and nitrosative stress, mitochondrial dysfunction, and impaired autophagy induce biochemical modifications such as carbonylation, nitration, hybrid insulin peptide formation, citrullination, deamidation, and defective ribosomal product generation. These processes generate distinct neoepitope classes that remodel the β-cell immunopeptidome and enhance immunogenicity.
1.2 Immunometabolism: a framework linking metabolism to immune recognition
The concept of immunometabolism provides a unifying framework for understanding these processes (13, 14). Immunometabolism describes how cellular metabolic pathways control immune-cell differentiation, activation, and effector function (15). Emerging evidence suggests that metabolic intermediates act not only as energy sources, but also as signaling molecules that influence transcription, translation, and epigenetic modification. In the context of T1D, both immune and non-immune cells operate within a shared metabolic network in which alterations in glucose, lipid, and amino acid metabolism reshape immune recognition.
1.3 Metabolic regulation of antigen-presenting cells
Within this framework, antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells also undergo profound metabolic adaptations in response to environmental cues (16). Their ability to process and present antigens is tightly regulated by nutrient-sensing pathways, including mechanistic target of rapamycin complex 1 (mTORC1), AMP-activated protein kinase (AMPK), and the integrated stress response mediated by the general control non-derepressible 2 (GCN2) kinase (17, 18). Activation of glycolytic metabolism enhances pro-inflammatory cytokine production and co-stimulatory molecule expression, whereas reliance on oxidative phosphorylation is often associated with tolerogenic or anti-inflammatory phenotypes (19–22). These distinct metabolic states determine whether an APC promotes immune tolerance or triggers effector T-cell activation.
1.4 A unifying hypothesis: β-cell and immune-cell metabolic stress as a shared axis of disease
The hypothesis advanced in this perspective is that metabolic stress within β-cells and APCs constitutes a unifying axis that underpins the initiation and propagation of T1D. In β-cells, ER stress, mitochondrial dysfunction, and oxidative imbalance remodel the antigenic landscape through altered peptide processing and post-translational modifications (PTMs) (10). These processes give rise to modified self-peptides and hybrid epitopes that are efficiently presented on upregulated MHC-I molecules. Simultaneously, APCs exposed to the metabolic and inflammatory milieu of the islet adapt their bioenergetic programs in a manner that enhances antigen uptake, processing, and presentation. Nutrient deprivation, hypoxia, and cytokine signaling converge on metabolic checkpoints that bias APCs toward an immunogenic presentation mode (23).
1.5 Establishment of a feed-forward β-cell–APC immunometabolic loop
The interaction between these two stressed cell populations generates a feed-forward loop of autoimmunity. Metabolically stressed β-cells release danger-associated molecular patterns and neoantigens that are captured and presented by metabolically reprogrammed APCs. In turn, activated APCs secrete pro-inflammatory cytokines such as type I interferons (IFN), tumor necrosis factor (TNF), and interleukin-1β (IL-1β), which exacerbate β-cell stress, increase MHC-I expression on β-cells, and promote further antigen generation and immune activation. This reciprocal amplification may begin years before the onset of hyperglycemia and could represent the earliest cellular event in autoimmune diabetes.
1.6 Reframing T1D as a disorder of cellular homeostasis
Understanding T1D through the lens of immunometabolism therefore reframes the disease as a disorder of cellular homeostasis rather than as a purely immune-mediated attack. The β-cell and the immune system are metabolically intertwined, and the disruption of this metabolic dialogue contributes to the failure of immune tolerance. By elucidating the molecular mechanisms linking metabolism, redox signaling, and antigen presentation, new therapeutic strategies can be envisioned that restore β-cell resilience and recalibrate APC function before irreversible β-cell loss occurs.
2 β-cell metabolic stress and antigenicity
The pancreatic β-cell is a highly specialized endocrine cell that maintains glucose homeostasis through rapid and tightly regulated secretion of insulin (24, 25). This demanding function requires continuous synthesis, folding, and trafficking of insulin molecules and depends on finely balanced mitochondrial and ER activity. As the β-cell possesses limited antioxidant defenses and a relatively small capacity for protein quality control, it is exceptionally vulnerable to metabolic perturbation. Conditions such as nutrient excess, viral infection, and local inflammation easily disturb its homeostasis, generating stress responses that impair insulin secretion and alter the antigenic characteristics of the cell surface. These metabolic disturbances produce reactive oxygen and nitrogen species, perturb redox signaling, and promote organelle dysfunction. The combined effect is an increase in both β-cell fragility and immune visibility (Table 1).
Table 1. Metabolic stress pathways in β-cells and their impact on antigen presentation.
2.1 ER stress and UPR
The ER is the site where insulin is synthesized, folded, and assembled before secretion (26–28) (Figure 2). During sustained secretory demand or exposure to inflammatory cytokines, misfolded proteins accumulate in the ER lumen and activate the unfolded protein response (29, 30). This adaptive mechanism is mediated by the protein kinase RNA-like ER kinase pathway (PERK), the inositol-requiring enzyme 1 alpha pathway (IRE1α), and the activating transcription factor 6 (ATF6) pathway (26) (Figure 2). In β-cells, transient activation of the UPR reduces translation, increases the production of molecular chaperones, and restores homeostasis. Persistent activation, however, induces apoptotic and inflammatory transcriptional programs through CCAAT/enhancer-binding protein homologous protein (CHOP), c-Jun N-terminal kinase (JNK), and nuclear factor kappa B (NF-κB).
Figure 2. Intracellular integration of β-cell stress pathways in antigen presentation. Metabolic stress within pancreatic β-cells coordinates mitochondrial, endoplasmic-reticulum (ER), and proteasomal responses that enhance antigen visibility. ER stress activates IRE1α and ATF6, increasing peptide-loading capacity and MHC-I expression. Mitochondrial dysfunction produces reactive oxygen species (ROS) and releases mitochondrial DNA (mtDNA), driving oxidative modifications such as protein carbonylation. Proteasomal degradation of oxidized and hybrid insulin peptides yields fragments that are transported into the ER via TAP1/2 for assembly with MHC molecules. The convergence of oxidative stress, organelle crosstalk, and altered peptide processing transforms the β-cell into an active antigen-presenting unit, establishing a mechanistic link between metabolic imbalance and autoimmune activation in type 1 diabetes. Created in BioRender. Mittal, R. (2026) https://BioRender.com/cq8jzkk.
These stress pathways influence antigen processing as well as cell survival (24, 25, 31). Splicing of X-box-binding protein 1 (XBP1) enhances transcription of genes that encode peptide-loading components, while the PERK pathway alters global translation and changes the pool of peptides available for binding to MHC-I molecules (32–34). Studies of human and rodent islets show that prolonged ER stress increases the expression of transporter associated with antigen processing 1 and 2 (TAP1/2), β-2-microglobulin, and other elements of the antigen-presentation machinery (35–37). ER stress therefore expands the diversity of peptides processed for MHC-I presentation and sensitizes β-cells to type I IFN, which further increase MHC-I expression and presentation of β-cell–derived antigens (6, 38, 39).
2.2 Mitochondrial dysfunction and redox imbalance
Mitochondria are the central regulators of β-cell metabolism as oxidative phosphorylation (OXPHOS) links glucose oxidation to the generation of adenosine triphosphate (ATP) required for insulin exocytosis (40). Impaired mitochondrial respiration increases the production of ROS such as superoxide and hydrogen peroxide (41). In β-cells, these oxidants modify proteins and lipids, generating carbonylated and nitrosylated derivatives that act as novel antigenic determinants (42–44). A persistent oxidative shift in the intracellular redox state alters disulfide bond formation within proinsulin and other secretory proteins, producing misfolded molecules that are processed differently by the proteasome (45–47). These modified peptides enlarge the spectrum of antigens that can be presented on MHC-I molecules (48, 49). Through these mechanisms, mitochondrial ROS directly contribute to β-cell neoantigen generation.
By contrast, mitochondrial damage can also lead to the release of mitochondrial DNA and the phospholipid cardiolipin, which function as danger-associated molecular patterns (DAMPs) once encountered by immune cells. In APCs, these mitochondrial components engage innate immune receptors such as cyclic GMP–AMP synthase (cGAS) and toll-like receptor 9 (TLR-9) (50, 51). Activation of these sensors stimulates type I IFN signaling and the transcription of genes involved in antigen processing (38, 52).
2.3 Neoepitope formation through oxidative and redox-dependent mechanisms
One of the most significant consequences of metabolic stress within β-cells is the creation of neoepitopes that are unfamiliar to the immune system (53) (Figure 3). Here, β-cell–intrinsic metabolic stress responses reshape the β-cell immunopeptidome by amplifying ER stress, mitochondrial dysfunction, and oxidative injury (54). These perturbations expand the pool of stress-modified peptides and neoepitopes presented on MHC-I molecules, thereby heightening β-cell immunogenicity and promoting early autoimmune recognition (54). Reactive oxygen and nitrogen species alter amino acid side chains, changing charge and conformation of epitopes as well as increasing their affinity for specific HLA alleles (38). Within secretory granules, oxidative conditions promote transpeptidation reactions between fragments of insulin and other granule proteins such as chromogranin A or islet amyloid polypeptide (55). The resulting hybrid insulin peptides (HIPs) are generated within β-cells, displayed at the cell surface, and recognized by autoreactive CD4+ T cells (38, 56). However, evidence for CD8+ T-cell recognition of HIP-derived epitopes or their presentation by MHC-I remains still unclear.
Figure 3. Mechanisms underlying β-cell neoepitope generation. Diverse metabolic and oxidative stress pathways within pancreatic β-cells converge to reshape the antigenic landscape and promote neoepitope formation. Endoplasmic reticulum stress triggers the unfolded protein response (UPR), leading to altered peptide processing and diversification of the MHC class I–associated peptide pool. Mitochondrial dysfunction induces the release of reactive oxygen species (ROS) and mitochondrial DNA (mtDNA), which activate cytosolic and endosomal sensors, including cGAS and TLR9, culminating in MHC-I hyperexpression through JNK and NF-κB signaling. Concurrent oxidative and nitrosative modifications, such as carbonylation, foster the generation of hybrid insulin peptides, whereas impaired autophagy and mitophagy result in the accumulation of damaged organelles and sustained antigen presentation. Collectively, these mechanisms expand the β-cell immunopeptidome and potentiate immune recognition, establishing a molecular basis for autoimmune activation in type 1 diabetes.
Extending these observations, recent ultrastructural mapping of the 6.9 HIP using a HIP-specific monoclonal antibody (6.9HIP-MAb) revealed that HIP epitopes localize not only within insulin-positive β-cells but also inside intra-islet antigen-presenting cells in NOD mice (57). Immunogold electron microscopy showed 6.9HIP concentrated within dense-core granules (DCGs) and in granule–lysosomal hybrid compartments marked by LAMP1, indicating that HIP formation or processing occurs within the crinosome/lysosomal axis rather than solely in secretory granules. Notably, induction of ER stress by tunicamycin markedly increased 6.9 HIP abundance in DCG- and crinosome-enriched fractions, establishing a direct mechanistic link between β-cell proteostatic stress and enhanced formation or accumulation of HIP neoantigens (57).
Nitrosative stress contributes further to the diversification of the β-cell immunopeptidome (6, 58, 59). Cytokine-induced expression of inducible nitric oxide synthase (iNOS) leads to production of peroxynitrite, which nitrates tyrosine residues in insulin and other proteins. These nitrated peptides resist degradation by conventional proteasomes and generate unusual cleavage products that enter the MHC pathway (60, 61). The cumulative result of oxidative and nitrosative modification is an expanded set of presented peptides capable of breaking immune tolerance (62–64).
In addition to HIPs, several other biochemical pathways generate neoepitopes during metabolic and inflammatory stress in T1D (10, 65–67) (Figures 1, 3). Carbonylation represents a major oxidative modification that occurs when ROS alter amino acid side chains and convert lysine, arginine, threonine, and proline residues into carbonyl containing groups (68). This highly stable modification changes peptide structure, proteasomal processing, and binding affinity for HLA-I particularly in the presence of mitochondrial dysfunction and elevated ROS (69). Deamidation of asparagine and glutamine residues also contributes to neoepitope formation (67). This reaction increases in acidic and inflamed microenvironments and during prolonged ER stress. Deamidated peptides often display altered charge distribution and can bind HLA-II molecules with increased efficiency.
Citrullination provides another important source of neo-antigens (70, 71). This modification is catalyzed by peptidyl arginine deiminase (PAD) enzymes, which convert arginine into citrulline. PAD activity increases in response to calcium influx, oxidative stress, and exposure to proinflammatory cytokines (72). Citrullinated proteins have been reported in pancreatic islets under inflammatory conditions, and these modified peptides are efficiently processed and presented by APCs that undergo glycolytic metabolic reprogramming (73, 74). Defective ribosomal products (DRiPs) form an additional category of stress-induced neoantigens (75). Activation of the unfolded protein response, (UPR), and the integrated stress response reduces translational fidelity and leads to production of short-lived polypeptides that are rapidly targeted to the proteasome. In cytokine stimulated β-cells and APCs, immunoproteasome induction increases the efficiency with which DRiPs are processed into high affinity ligands for HLA-I molecules.
Together, carbonylation, deamidation, citrullination, and defective ribosomal product generation illustrate how metabolic stress, oxidative injury, and inflammatory signaling reshape the biochemical landscape of antigen formation. These mechanisms progressively widen the diversity of peptides available for presentation and increase the immunological visibility of β-cells. Integrating these established pathways into the broader immunometabolic framework clarifies how microenvironmental cues and cellular metabolism influence both the quality and quantity of neoepitopes that contribute to the initiation and progression of T1D.
2.4 Human leukocyte antigen class I hyper-expression and immunopeptidome remodeling
Analyses of pancreatic tissue from individuals in the pre-diabetic and early diabetic stages consistently show pronounced overexpression of human leukocyte antigen (HLA)-I molecules on β-cells (6, 76–79). This phenomenon appears before substantial immune infiltration and may represent an intrinsic response to metabolic and inflammatory stress (77, 80). Type I interferons produced locally activate the Janus-kinase–signal-transducer-and-activator-of-transcription pathway (JAK–STAT) and drive transcription of the HLA-I genes (78, 81, 82). Proteomic mapping of interferon-treated human islets demonstrates both increased surface abundance of class I molecules and a qualitative shift in the presented peptides, with a predominance of HLA-B-restricted epitopes enriched in stress-modified sequences (6, 38, 78, 83). This remodeling enhances recognition of β-cells by cytotoxic lymphocytes and accelerates autoimmune destruction (84–87).
Interferon signaling also induces the formation of immunoproteasomes that generate peptides with C-terminal residues optimized for class I binding (82, 88, 89). The combined induction of immunoproteasomes and peptide-loading machinery ensures efficient presentation of stress-derived antigens and links metabolic perturbation directly to the activation of adaptive immunity (90).
2.5 Autophagy and mitophagy in antigen processing
Autophagy is the principal mechanism by which cells remove misfolded proteins and damaged organelles (91–93). In β-cells, autophagy deficiency leads to accumulation of protein aggregates, distension of the ER, and fragmentation of mitochondria (8, 94, 95). Inhibition of autophagy increases ER stress and enhances expression of MHC-I molecules (8, 96, 97). Conversely, stimulation of autophagy restores protein quality control and diminishes antigen presentation (98, 99). The selective clearance of dysfunctional mitochondria through mitophagy prevents the release of mitochondrial DNA and other DAMPs that would otherwise trigger innate immune responses (100–102). Loss of mitophagy regulators such as PINK1 or Parkin in β-cells results in persistent inflammation and amplification of antigenic signals (103–105). Preservation of autophagic flux is therefore essential to limit the immunogenic consequences of metabolic stress (8, 93, 106).
The subsequent section examines how the metabolic state of APCs determines whether these antigens elicit immune tolerance or promote pathogenic immunity, and how continuous dialogue between metabolically stressed β-cells and reprogrammed APCs sustain the autoimmune process in T1D (86, 107) (Table 1).
3 Immunometabolic regulation of antigen presentation by APCs
APCs represent the crucial bridge between innate and adaptive immunity (Table 2). Within the context of T1D, dendritic cells, macrophages, and B cells operate as central mediators that capture β-cell–derived antigens and deliver them to T lymphocytes in pancreatic lymph nodes. These cells do not simply respond to cytokines and antigens; their functional phenotype is determined by their metabolic state. Cellular metabolism in APCs governs the rate and route of antigen uptake, processing, and presentation, and also influences the expression of co-stimulatory molecules that determine the outcome of T-cell activation. The immune and metabolic systems are therefore intertwined at a fundamental level. Understanding this relationship provides new insight into how metabolic cues within the pancreatic microenvironment shape the evolution of autoimmunity.
Table 2. Immunometabolic regulation of antigen presentation in Antigen-Presenting Cells (APCs).
3.1 The islet microenvironment and the metabolic landscape of APCs
The pancreatic islet is a metabolically active micro-organ in which insulin secretion and nutrient flux generate substantial variation in oxygen tension, glucose concentration, and lipid content (108–110). Islet-resident macrophages and dendritic cells are continuously exposed to this changing environment (86, 111). During the initial stages of insulitis, infiltrating immune cells and stressed β-cells release cytokines, reactive oxygen species (ROS), and metabolic by-products that remodel the local milieu. Hypoxia, nutrient deprivation, and accumulation of lactate and fatty acids alter the bioenergetic programs of islet macrophages (23, 108, 110).
Under basal conditions, islet macrophages rely on OXPHOS to maintain tissue homeostasis and phagocytic clearance of apoptotic β-cells without eliciting inflammation (112–115). In contrast, during inflammation, activation of TLRs or exposure to cytokines such as IFN-γ induces a metabolic switch toward glycolysis (116). This glycolytic reprogramming supports pro-inflammatory mediator synthesis and enhances MHC-II–restricted presentation of captured β-cell antigens, together with increased co-stimulation (117). Single-cell transcriptomic analyses of human and murine islets confirm that the shift from oxidative to glycolytic metabolism is accompanied by increased expression of MHC-II molecules, co-stimulatory ligands, and cytokines that promote T-cell activation (25, 118).
3.2 Nutrient-sensing and stress-responsive signaling in APCs
Nutrient-sensing pathways function as molecular rheostats that adjust the immune capacity of APCs to their metabolic environment (119, 120). The mechanistic target of rapamycin complex 1 integrates signals from amino acids, glucose, and growth factors to promote anabolic metabolism and pro-inflammatory activity (119, 121–123). Activation of this pathway enhances glycolytic flux and supports the production of IL-12 and other cytokines that favor T helper type 1 polarization (120, 123–125). In contrast, activation of AMPK favors oxidative metabolism, mitochondrial biogenesis, and anti-inflammatory or tolerogenic phenotypes (126, 127).
Another critical regulator is the general control non-derepressible 2 kinase (GCN2), which detects amino acid deprivation and triggers the integrated stress response (128–130). Engagement of this pathway modifies mRNA translation and activates transcription factors such as activating transcription factor 4 (ATF-4), which can influence antigen-processing genes (129, 130). When nutrients are scarce, activation of this stress response may paradoxically increase antigen presentation while impairing the induction of regulatory signals, thereby promoting autoreactivity. Collectively, these nutrient sensors coordinate metabolic activity with immune function and determine whether an APC promotes tolerance or immunity.
3.3 Influence of lipid metabolism on antigen processing
Lipid metabolism exerts profound effects on antigen presentation (131–134). In APCs, accumulation of intracellular lipid droplets interferes with endosomal trafficking and the assembly of peptide–MHC complexes (15, 135–138). In metabolic disorders characterized by hyperlipidemia or obesity, this phenomenon contributes to immune dysfunction (132, 134, 139). Within the pancreatic islet, elevated levels of free fatty acids and oxidized lipids derived from stressed β-cells can modify the lipid composition of macrophage membranes and endosomes (140, 141). These alterations may impair the processing of conventional peptide antigens while enhancing the presentation of lipid antigens through CD1 molecules (133, 142–144). Lipid-reactive natural killer T cells, which recognize glycolipid antigens, are increasingly implicated in the regulation of autoimmunity and may play an underappreciated role in T1D (145, 146).
Lipid peroxidation products such as 4-hydroxynonenal (4-HNE) can form covalent adducts with proteins within APCs, generating modified self-molecules that act as adjuvants or new epitopes (147–149). These products also activate nuclear receptors such as peroxisome proliferator-activated receptors (PPARγ), which in turn modulate gene expression related to metabolism and antigen presentation (150, 151). The integration of lipid metabolic signals with immune signaling thus provides another axis of regulation that determines the immunogenic potential of islet APCs.
3.4 Mitochondrial function and redox signaling in APC activation
Mitochondria in APCs serve not only as energy generators but also as regulators of redox balance and innate immune signaling (152–154). Whereas MHC-II presentation is typically increased during inflammatory glycolytic activation, mitochondrial ROS signaling can be particularly important for cross-presentation of exogenous β-cell antigens on MHC-I. Controlled production of mitochondrial ROS is necessary for efficient antigen cross-presentation because low-level oxidative bursts promote the release of endosomal antigens into the cytosol where they are processed for MHC-I presentation (155, 156). Excessive mitochondrial oxidative stress, however, damages peptides and impairs peptide loading onto MHC molecules (156–160).
Mitochondrial metabolism also contributes to the generation of metabolites such as succinate and fumarate, which function as signaling molecules (161–164). Succinate accumulation stabilizes hypoxia-inducible factor 1 alpha (HIF1α), thereby enhancing glycolytic metabolism and promoting the expression of pro-inflammatory genes (165–168). In contrast, intact tricarboxylic acid cycle (TCA) activity and efficient OXPHOS are associated with anti-inflammatory and tolerogenic functions (169, 170). The balance between these metabolic programs influences whether the APC induces effector T-cell responses or regulatory T-cell differentiation (171).
3.5 Hypoxia, lactate accumulation, and the metabolic polarization of APCs
Inflamed pancreatic islets often experience local hypoxia because of immune cell infiltration and vascular disruption (23, 110, 172). Hypoxia stabilizes HIF1α, a transcription factor that promotes glycolytic metabolism and enhances the expression of iNOS and co-stimulatory molecules (15, 98, 173). Hypoxia-induced metabolic polarization supports antigen presentation and increases the production of cytokines such as TNF and IL-1 β, both of which intensify β-cell stress (98, 137).
Simultaneously, hypoxic metabolism increases the generation of lactate, which has context-dependent effects on immune cells (174–178). In tolerogenic dendritic cells, lactate accumulation can inhibit nuclear factor kappa B (NF-κB) activation and reduce co-stimulatory molecule expression, whereas in pro-inflammatory settings, lactate serves as an additional substrate for histone acetylation, promoting transcription of inflammatory genes (176, 177, 179). The net effect in the diabetic islet is complex but tends toward inflammation because of the concurrent presence of interferons and cytokines that dominate over tolerogenic influences (180).
4 Reciprocal crosstalk between β-cells and antigen-presenting cells
The interaction between pancreatic β-cells and APCs forms a central pathogenic circuit in T1D. The two cell types engage in continuous bidirectional communication through soluble mediators, metabolic signals, and direct cell-to-cell contact (Table 3). Metabolic stress in β-cells alters the repertoire of antigens that are released and modifies the extracellular environment, whereas APCs respond to these cues by changing their metabolic state and immune behavior. This reciprocal communication amplifies inflammation and accelerates the breakdown of immune tolerance (Table 3; Figure 4).
Table 3. Reciprocal crosstalk between β-Cells and Antigen-Presenting Cells (APCs) in Type 1 diabetes.
Figure 4. Immunometabolic remodeling of β cells drives neoantigen generation and autoimmune amplification in type 1 diabetes. Metabolic stress in pancreatic β cells induced by proinflammatory cytokines nutrient imbalance and mitochondrial dysfunction promotes oxidative and nitrosative stress with increased reactive oxygen and nitrogen species. These perturbations disrupt proteostasis and redox homeostasis leading to post translational modifications defective protein processing and neoepitope formation. Stressed β cells upregulate major histocompatibility complex (MHC)-I enhancing presentation of modified self-peptides. Neoantigens released from stressed or dying β cells are captured by antigen presenting cells that undergo metabolic and redox reprogramming to enhance antigen processing and presentation. Activation of autoreactive T cells establishes a feed forward inflammatory loop that amplifies immune responses and accelerates progressive β cell destruction linking immunometabolic stress to loss of immune tolerance in type 1 diabetes. Created in BioRender. Mittal, R. (2026) https://BioRender.com/9sr96th.
4.1 Release of danger signals and modified antigens from stressed β-cells
Under metabolic or oxidative stress, β-cells release a variety of danger-associated molecular patterns, including heat-shock proteins, mitochondrial DNA, high-mobility group box 1 protein (HMGB1), and extracellular ATP (78, 181, 182) (Figure 4). These molecules activate pattern-recognition receptors (PRRs) on macrophages and dendritic cells, such as TLRs and the nucleotide-binding oligomerization domain-like receptor family (NLR), leading to the production of inflammatory cytokines. Simultaneously, apoptotic and necrotic β-cells release intracellular proteins that have undergone oxidative or nitrosative modification. These altered proteins serve as a rich source of potential autoantigens. Once taken up by APCs, they are processed and loaded onto MHC-II molecules (with cross-presentation onto MHC-I in appropriate APC subsets) for presentation to autoreactive T lymphocytes.
The presence of ROS within the islet microenvironment not only modifies proteins but also oxidizes extracellular lipids and nucleic acids, which can further stimulate innate immune receptors. This combination of danger signals and modified self-antigens transforms the islet from a quiescent metabolic organ into a site of persistent immune activation.
4.2 Antigen uptake, processing, and metabolic activation of APCs
APCs in the islet and in the draining pancreatic lymph node internalize β-cell-derived material through phagocytosis, receptor-mediated endocytosis, and micropinocytosis (183). The metabolic state of these cells influences how efficiently they process these antigens. Inflammatory cytokines, such as interferon gamma, promote glycolytic reprogramming, which enhances the expression of proteasome components, peptide transporters, and co-stimulatory molecules (6). This metabolic activation increases the likelihood that β-cell antigens will be presented in a highly immunogenic context. In this setting, APC activation primarily augments MHC-II presentation of β-cell antigens, while also increasing the efficiency of cross-presentation on MHC-I.
Conversely, when OXPHOS predominates and nutrients are scarce, APCs exhibit a more tolerogenic profile characterized by limited co-stimulation and secretion of anti-inflammatory mediators (173). In T1D, however, chronic exposure to cytokines, hypoxia, and high levels of free fatty acids skews the metabolic balance toward glycolysis and sustains inflammatory antigen presentation (23). The result is a persistent population of activated dendritic cells and macrophages that maintain autoreactive T-cell stimulation (111).
4.3 Metabolic coupling and nutrient competition
The inflamed islet represents a metabolically competitive environment (184, 185). Infiltrating immune cells consume glucose and amino acids, reducing nutrient availability for neighboring β-cells (122, 186, 187). This deprivation triggers integrated stress responses in both cell types (188). In β-cells, reduced glucose uptake suppresses insulin biosynthesis but increases oxidative stress through mitochondrial inefficiency (110, 189–191). In APCs, nutrient scarcity activates the GCN2 and shifts translation toward stress-responsive genes that support antigen presentation and cytokine production (192–195).
Competition for oxygen further exacerbates this relationship (23, 184, 196). As inflammation progresses, vascular perfusion becomes impaired, generating local hypoxia that stabilizes HIF1α in macrophages and dendritic cells (122, 179, 184). This stabilization drives glycolytic metabolism and pro-inflammatory gene expression (122, 173). The same hypoxic environment damages β-cell mitochondria, enhancing ROS formation and the release of mitochondrial components that serve as innate immune triggers (197, 198). Thus, metabolic coupling through shared resources and microenvironmental changes reinforces pathological communication between the two cell populations (184, 185).
5 Translational perspectives and therapeutic implications
Understanding the metabolic relationship between pancreatic β-cells and APCs reveals new therapeutic opportunities (Table 4). Traditional strategies for T1D have focused primarily on immune suppression or antigen-specific tolerance induction. Although these approaches can delay disease progression, they rarely prevent relapse as the underlying metabolic stress that drives antigen generation and presentation remains uncorrected. A complementary strategy aims to restore metabolic homeostasis within both β-cells and APCs, thereby reducing antigenicity and dampening immune activation at its source (Figure 5).
Table 4. Therapeutic strategies targeting the immunometabolic interface.
Figure 5. Immunometabolic targeting of the β-cell–APC axis in type 1 diabetes. Metabolic and oxidative stress in β-cells induces ER stress, redox imbalance, post-translational modifications, impaired autophagy, and neoepitope generation, enhancing antigenicity. Interventions that reduce ROS/RNS, inhibit PTM pathways (e.g., PAD inhibition), and restore autophagy stabilize β-cell proteostasis and limit antigen production. Concurrently, APCs undergo inflammatory metabolic reprogramming characterized by increased mTOR signaling and glycolysis. Rewiring APC metabolism toward AMPK activation and mTOR suppression promotes tolerogenic antigen processing and presentation. Integrated β-cell– and APC-directed immunometabolic strategies may disrupt feed-forward autoimmunity and restore immune tolerance in type 1 diabetes. Created in BioRender. Mittal, R. (2026) https://BioRender.com/j8d9or0.
5.1 Restoring β-cell proteostasis and metabolic stability
β-cell stress is the initial spark that ignites immune recognition (8). Interventions that preserve protein-folding capacity, reduce oxidative injury, or enhance organelle quality control can attenuate this process (199). Small-molecule chaperones such as tauroursodeoxycholic acid and 4-phenylbutyric acid assist in the resolution of ER stress by stabilizing protein conformation and facilitating proper folding (200–202). Experimental studies in rodent models demonstrate that these agents reduce expression of inflammatory genes, normalize insulin synthesis, and protect β-cell mass (199, 203). Pharmacologic activators of nuclear factor erythroid 2–related factor 2 (Nrf2) enhance the antioxidant defense system, decreasing ROS formation and preventing the oxidative modifications that give rise to neoantigens (44, 199).
Mitochondria-targeted antioxidants such as MitoQ and SkQ1 scavenge ROS directly within the mitochondrial matrix (204–206). Their use in preclinical models lowers lipid peroxidation, reduces cytokine production, and maintains insulin secretion (207–210). Agents that stimulate autophagy, including trehalose and spermidine, promote clearance of misfolded proteins and damaged mitochondria, restoring proteostasis and limiting the accumulation of potentially immunogenic debris (211–213). Collectively, these interventions reinforce the natural adaptive stress responses of the β–cell and decrease its visibility to the immune system.
5.2 Targeting PTM pathways to limit neoantigen generation
In addition to therapeutic strategies aimed at mitigating oxidative stress and ER stress, direct targeting of PTM pathways that contribute to neoantigen formation represents a complementary approach for modifying the progression of autoimmune diabetes (214–217). PTMs alter the biochemical and structural properties of β-cell proteins, generating antigenic determinants that are not encountered during thymic selection and therefore evading central tolerance (218–220). As a result, these modified epitopes exhibit an increased likelihood of recognition by autoreactive T cells (221, 222). Among the PTMs implicated in β-cell autoimmunity, protein citrullination has emerged as a particularly significant source of β-cell neoepitopes (217, 219, 221).
Citrullination is mediated by PAD enzymes, whose activity is regulated by intracellular calcium flux and is enhanced under conditions of metabolic stress and inflammatory signaling (217, 223). In β-cells, these stress associated cues promote the conversion of arginine residues to citrulline within key autoantigens, leading to altered peptide processing, modified MHC binding properties, and changes in TCR engagement (219, 221). The resulting citrullinated peptides expand the β-cell immunopeptidome and increase the probability of immune recognition by autoreactive lymphocytes.
Pharmacologic inhibition of PAD activity has provided direct experimental evidence supporting a pathogenic role for citrullination in autoimmune diabetes (214). In the NOD mouse model, PAD inhibition reduces the accumulation of citrullinated β-cell proteins, limits the availability of modified antigenic peptides, and attenuates autoreactive T cell activation (214, 224). These immunologic effects are associated with delayed disease onset and a reduced incidence of diabetes, demonstrating that suppression of neoantigen generation can produce meaningful disease modification in vivo.
Targeting PTM pathways addresses a distinct pathogenic axis that operates upstream of immune effector activation (214, 224). Rather than broadly suppressing inflammatory signaling or adaptive immune responses, PAD inhibition selectively limits the formation of highly immunogenic antigens while preserving basal immune competence. This antigen focused strategy complements approaches aimed at modulating β-cell stress responses or immune cell metabolic programs and highlights neoantigen generation as a mechanistically defined and therapeutically amenable target. Collectively, these findings support the concept that limiting the production of stress induced neoantigens at their cellular source can reshape immune recognition and alter the trajectory of autoimmune diabetes. Therapeutic strategies that constrain PTM driven antigen diversification may therefore contribute to the preservation of immune tolerance and long-term β-cell function, particularly when implemented during early or pre symptomatic stages of disease (214, 224).
5.3 Modulating β-cell redox and signaling networks
Control of the cellular redox environment provides an additional layer of therapeutic leverage. Redox-active signaling regulates not only oxidative defense but also gene transcription, calcium homeostasis, and apoptosis (225, 226). Modest activation of redox-sensitive pathways through physiological stressors such as intermittent fasting or mild caloric restriction induces adaptive hormesis, enhancing cellular resilience (227). Conversely, chronic oxidative overload triggers maladaptive signaling that promotes inflammation and antigen presentation (228). Pharmacologic manipulation of the glutathione and thioredoxin systems, as well as supplementation with precursors of nicotinamide adenine dinucleotide, can restore a balanced redox tone (229).
The regulation of cytokine receptor signaling also intersects with metabolic pathways. Inhibition of the JAK–STAT axis reduces interferon-driven expression of MHC-I molecules and lowers antigenic load (230). Such approaches must be applied judiciously to avoid generalized immune suppression, but transient modulation during early disease stages may shift the balance toward tolerance (231).
5.4 Reprogramming antigen-presenting cell metabolism
Parallel to the protection of β-cells, therapeutic benefit may be achieved by redirecting the metabolic programming of APCs (18, 232–234). The mechanistic target of rapamycin complex 1 is a key driver of glycolytic, pro-inflammatory metabolism (235–237). Inhibition of this pathway through rapamycin analogs or caloric restriction enhances OXPHOS and promotes a tolerogenic phenotype characterized by reduced production of IL-12 and TNF (238–240). In contrast, activation of AMPK increases mitochondrial biogenesis and drives expression of genes associated with anti-inflammatory cytokines such as interleukin 10 (18, 241, 242).
Other interventions exploit metabolic checkpoints associated with amino acid sensing (243–245). Activation of the GCN2 pathway by limited amino acid availability suppresses translation of inflammatory mediators and can promote immune tolerance if properly controlled (246–248). Supplementation with specific metabolites such as tryptophan or arginine can further modulate immune function through their roles in regulatory pathways and nitric oxide synthesis (249–251).
Lipid metabolism also provides an avenue for intervention (252–254). The PPARγ agonists regulate lipid uptake and storage and have been shown to reduce inflammation in macrophages (255, 256). By normalizing lipid metabolism within APCs, these agents may restore the balance between antigen clearance and presentation (18, 257).
5.5 Combination strategies and timing of intervention
The immunometabolic feedback loop linking β-cells and APCs suggests that effective therapy will likely require simultaneous modulation of both cell types (8, 38). Combination approaches could pair an ER chaperone or mitochondrial antioxidant with an agent that redirects APC metabolism toward tolerance. This dual modulation would both decrease antigen generation and reduce immune responsiveness to remaining antigens (18).
The earliest stages of T1D, when autoantibodies appear but insulin secretion remains measurable, offer the greatest potential for intervention as timing is critical (258, 259). At this stage, β-cell stress is still reversible, and the immune system retains plasticity. Clinical monitoring tools such as proinsulin-to-C-peptide ratio, circulating interferon-stimulated gene expression, and metabolic imaging can help identify individuals in this window (260, 261). Intervening before extensive β-cell destruction occurs may facilitate in slowing or halting the disease process (262).
5.6 Technological advances enabling metabolic therapy
Emerging technologies facilitate the translation of these concepts into clinical application. Single-cell transcriptomic and metabolomic analyses allow detailed mapping of metabolic states in β-cells and immune cells from human donors (263–265). Real-time metabolic flux assays and noninvasive imaging techniques can monitor the effects of therapy on cellular bioenergetics (264, 266–270). The integration of these tools with computational modeling will permit precise adjustment of therapeutic regimens to individual metabolic profiles.
Advances in nanotechnology and biomaterials further enhance the specificity of metabolic interventions. Nanoparticles can deliver antioxidants, small interfering RNA, or metabolic modulators directly to pancreatic islets, minimizing systemic side effects (271, 272). Encapsulation of β-cells in biomaterials engineered to modulate local oxygen and nutrient gradients offers another route to protect transplanted or regenerating cells from immune attack (273, 274).
6 Biomarkers and future research directions
The elucidation of metabolic and immune interactions in T1D has created new opportunities for identifying biomarkers that reflect the earliest pathogenic changes in both β-cells and APCs (Table 5). These biomarkers can serve as indicators of disease risk, guides for therapeutic intervention, and quantitative measures of treatment efficacy. The integration of metabolic, immunologic, and molecular readouts offers a comprehensive approach to disease monitoring and provides a foundation for precision medicine.
Table 5. Emerging biomarkers of immunometabolic dysfunction in type 1 diabetes.
6.1 Biomarkers of β-cell stress and antigenicity
β-cell stress is characterized by a constellation of molecular and biochemical alterations that can be measured in blood or in isolated islets (25, 260). Elevated circulating proinsulin relative to C-peptide is a well-validated indicator of impaired proinsulin processing and ER dysfunction (275–277). This ratio increases months to years before the onset of hyperglycemia and therefore serves as an early warning of β-cell stress. Additional biomarkers include the release of ER chaperones such as glucose-regulated protein 78 (GRP78), the up-regulation of CHOP in islet tissue, and the detection of fragments of insulin or proinsulin containing oxidative modifications (24, 278, 279).
Circulating cell-free mitochondrial DNA provides another readout of metabolic distress (280, 281). Elevated levels of mitochondrial DNA are associated with the release of DAMPs and correlate with IFN-stimulated gene signatures in peripheral blood (282–284). Measurements of ROS and antioxidant enzyme activity in plasma also provide indirect evidence of systemic oxidative stress (285). Together, these markers capture distinct aspects of the β-cell response to metabolic challenge and can be used to monitor the impact of therapies aimed at restoring cellular homeostasis.
6.2 Immunopeptidomic profiling and detection of neoantigens
Advances in mass spectrometry have enabled the direct characterization of the peptides bound to HLA molecules in islet tissue and in peripheral blood mononuclear cells (6, 42). Immunopeptidomic profiling can identify stress-induced peptides, HIPs, and oxidatively modified epitopes that arise during disease progression. Quantitative changes in the abundance or composition of these peptides can serve as molecular fingerprints of β-cell immunogenicity.
High-resolution mass spectrometric analysis can also detect differences in peptide presentation associated with specific HLA alleles, including the skewing toward HLA-B–restricted peptides that occurs after interferon exposure. Monitoring these changes in at-risk individuals may allow early identification of those transitioning from immune tolerance to active autoimmunity. The detection of circulating immune complexes containing neoantigenic peptides could further refine prediction of disease onset.
6.3 Biomarkers of APC metabolic state and antigen-presenting function
The metabolic polarization of APCs can be assessed through transcriptomic and metabolomic analyses of peripheral blood monocytes and dendritic cells (286–288). Expression patterns of genes involved in glycolysis, OXPHOS, and lipid metabolism reveal the predominant metabolic program (286, 289). Ratios of glycolytic to oxidative metabolites, such as lactate to citrate or succinate to fumarate, provide quantitative indicators of metabolic activity (167, 290, 291).
Flow cytometric analysis of co-stimulatory molecule expression combined with measurement of intracellular ATP and mitochondrial membrane potential allows direct assessment of APC activation (292–294). Single-cell RNA sequencing integrated with metabolite mapping can uncover subsets of APCs with distinct immunometabolic profiles that correlate with disease progression (265, 295, 296). These cellular and molecular signatures can be used to evaluate whether therapeutic interventions successfully reprogram APC metabolism toward a tolerogenic phenotype.
6.4 Integration of multi-omic biomarkers for personalized monitoring
The complexity of the immunometabolic network in T1D necessitates the integration of multiple layers of data. Multi-omic approaches that combine genomics, transcriptomics, proteomics, metabolomics, and immunopeptidomics provide a systems-level understanding of disease dynamics (297, 298). Machine-learning algorithms can identify biomarker combinations that predict progression from the preclinical stage to overt diabetes with high accuracy (299).
Longitudinal sampling of at-risk individuals can reveal temporal patterns of β-cell stress and immune activation, allowing the establishment of dynamic disease trajectories (300, 301). These trajectories can then guide the timing and intensity of therapeutic interventions. The use of standardized sample-collection protocols and analytical platforms will be essential to ensure reproducibility and comparability across studies.
6.5 Conceptual implications and outlook
The convergence of metabolism and immunity in the pathogenesis of T1D transforms the conceptual framework of the disease (302). It suggests that autoimmune destruction results not only from immune dysregulation but also from the failure of metabolic adaptation within the target tissue (303). This insight positions the β-cell as an active participant in disease initiation rather than a passive casualty.
Future progress will depend on the close collaboration between immunologists, metabolic biologists, and systems scientists. Integrating their perspectives will enable the construction of comprehensive models that capture the dynamic interplay among stress signaling, antigen presentation, and immune recognition. Such models will provide the basis for predictive diagnostics and rational therapeutic design.
In this view, successful management or prevention of T1D will rely on restoring cellular homeostasis rather than simply suppressing immune reactivity. Interventions that preserve the metabolic integrity of β-cells and recalibrate the energy metabolism of APCs hold the promise of transforming T1D from an inexorable autoimmune process into a controllable, and possibly reversible, metabolic disorder.
7 Concluding remarks
The integration of metabolic and immunologic research has fundamentally changed our understanding of T1D. The disease is no longer viewed solely as an autoimmune assault mediated by misdirected lymphocytes but rather as a complex disorder of cellular communication in which metabolic dysfunction initiates and sustains immune activation. Within this conceptual framework, β-cell and APCs emerge as equal partners in a pathological dialogue that drives the loss of immune tolerance and the destruction of pancreatic islets.
The evidence now supports the existence of a continuous immunometabolic loop in which stress within the β-cell and metabolic activation of APCs reinforce each other. In the β-cell, ER stress, mitochondrial dysfunction, and oxidative imbalance give rise to an altered immunopeptidome enriched in modified or hybrid peptides (10). These changes increase antigen visibility and provoke innate immune responses. At the same time, APCs exposed to inflammatory cytokines, hypoxia, and nutrient fluctuations adopt metabolic programs that favor glycolysis, production of ROS, and expression of co-stimulatory molecules (23). This metabolic polarization enhances antigen processing and cross-presentation, perpetuating autoreactive T-cell activation.
The persistent exchange of metabolic and inflammatory signals between these two cellular populations transforms the islet microenvironment into a self-sustaining immune niche. Cytokines such as IFN, TNF, and IL-1β amplify oxidative and ER stress, while reactive oxygen and nitrogen species propagate tissue damage and generate further neoantigens. The resulting feedback circuit not only accelerates β-cell loss but also stabilizes immune memory against self-antigens, making the autoimmune process resistant to conventional immunosuppression.
Recognition of this immunometabolic loop has far-reaching therapeutic implications. Interventions that restore metabolic equilibrium within the β-cell, reinforce antioxidant defenses, and preserve proteostasis can limit antigen generation at its origin. Likewise, modulation of APC metabolism through activation of adenosine monophosphate–activated protein kinase or inhibition of mechanistic target of rapamycin can re-establish a tolerogenic phenotype that restrains autoreactive T-cell activation. When these metabolic interventions are combined with antigen-specific immunotherapy, they offer the potential to reset the immune system without compromising host defense.
The conceptual shift from immune suppression to metabolic rehabilitation reframes the ultimate goal of therapy. The objective is no longer to silence the immune system but to reconstitute the physiological dialogue between immune cells and metabolic tissues. This approach envisions T1D diabetes as a reversible imbalance of cellular homeostasis that can be corrected by synchronizing metabolic and immune pathways.
Future research should pursue three interconnected goals. The first is to delineate the molecular mechanisms through which redox signaling and protein modification alter antigen presentation. The second is to identify biomarkers that accurately reflect immunometabolic states in vivo and that can guide early intervention. The third is to develop therapeutic combinations that simultaneously stabilize β-cell metabolism and recalibrate immune-cell energy utilization. Success in these areas will move the field from observation to intervention, transforming mechanistic insights into clinical benefit.
In summary, metabolic stress in β-cells and APCs constitutes a unifying axis that explains the initiation and propagation of autoimmune injury in T1D. The interactions between these cell types are mediated through shared metabolic pathways, redox signaling, and antigen-processing mechanisms that form a continuous and self-reinforcing circuit. Targeting this circuit represents a powerful strategy to preserve β-cell mass, restore immune tolerance, and ultimately alter the natural history of the disease. The synthesis of immunology and metabolism thus defines a new paradigm for understanding and treating T1D and may provide a blueprint for addressing other chronic autoimmune disorders rooted in metabolic dysfunction.
Author contributions
RM: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. RG: Conceptualization, Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing. MM: Conceptualization, Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing. NC: Conceptualization, Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing. VR: Conceptualization, Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing. KH: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Acknowledgments
We are grateful to Dr. Valerie Gramling for critical reading of the manuscript.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that Generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Aamodt KI and Powers AC. The pathophysiology, presentation and classification of Type 1 diabetes. Diabetes Obes Metab. (2025) 27(Suppl 6):15–27. doi: 10.1111/dom.16628
2. Ebrahimpour Y, Khatami S, Saffar M, Fereidouni A, Biniaz Z, Erfanian N, et al. A Comprehensive Review of Novel Advances in Type 1 Diabetes Mellitus. J Diabetes. (2025) 17:e70120. doi: 10.1111/1753-0407.70120
3. Bell KJ and Lain SJ. The Changing Epidemiology of Type 1 Diabetes: A Global Perspective. Diabetes Obes Metab. (2025) 27(Suppl 6):3–14. doi: 10.1111/dom.16501
4. Mauvais FX and van Endert PM. Type 1 Diabetes: A Guide to Autoimmune Mechanisms for Clinicians. Diabetes Obes Metab. (2025) 27(Suppl 6):40–56. doi: 10.1111/dom.16460
5. Mittal R, Camick N, Lemos JRN, and Hirani K. Gene-environment interaction in the pathophysiology of type 1 diabetes. Front Endocrinol (Lausanne). (2024) 15:1335435. doi: 10.3389/fendo.2024.1335435
6. Carré A, Samassa F, Zhou Z, Perez-Hernandez J, Lekka C, Manganaro A, et al. Interferon-α promotes HLA-B-restricted presentation of conventional and alternative antigens in human pancreatic β-cells. Nat Commun. (2025) 16:765. doi: 10.1038/s41467-025-55908-9
7. Bhushan A and Thompson PJ. Inflammatory β-Cell Stress and Immune Surveillance in Type 1 Diabetes. Cold Spring Harb Perspect Med. (2025) 15(7). doi: 10.1101/cshperspect.a041605
8. Austin MC, Muralidharan C, Roy S, Crowder JJ, Piganelli JD, and Linnemann AK. Dysfunctional β-cell autophagy induces β-cell stress and enhances islet immunogenicity. Front Immunol. (2025) 16:1504583. doi: 10.3389/fimmu.2025.1504583
9. Pipella J, Motlagh RA, Rampazzo Morelli N, and Thompson PJ. Autoreactive T Cells and Cytokine Stress Drive β-Cell Senescence Entry and Accumulation in Type 1 Diabetes. Diabetes. (2025) 74:1562–76. doi: 10.2337/db24-1122
10. Alhamar G, Vinci C, Franzese V, Tramontana F, Le Goux N, Ludvigsson J, et al. The role of oxidative post-translational modifications in type 1 diabetes pathogenesis. Front Immunol. (2025) 16:1537405. doi: 10.3389/fimmu.2025.1537405
11. Lytrivi M, Tong Y, Virgilio E, Yi X, and Cnop M. Diabetes mellitus and the key role of endoplasmic reticulum stress in pancreatic β cells. Nat Rev Endocrinol. (2025) 21:546–63. doi: 10.1038/s41574-025-01129-5
12. Mori S, Kohyama M, Yasumizu Y, Tada A, Tanzawa K, Shishido T, et al. Neoself-antigens are the primary target for autoreactive T cells in human lupus. Cell. (2024) 187:6071–87.e20. doi: 10.1016/j.cell.2024.08.025
13. Wang YH, Wang L, and Ho PC. Decoding immunometabolism with next-generation tools: lessons from dendritic cells and T cells. EMBO J. (2025). doi: 10.1038/s44318-025-00569-z
14. Tada M and Kono M. Metabolites as regulators of autoimmune diseases. Front Immunol. (2025) 16:1637436. doi: 10.3389/fimmu.2025.1637436
15. Li W, Yu C, Zhang X, Gu Y, He X, Xu R, et al. Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications. Mol Biomed. (2025) 6:62. doi: 10.1186/s43556-025-00300-8
16. Murokawa H, Egusa K, Shibutani S, and Iwata H. Mechanistic/mammalian target of rapamycin complex 1 (mTORC1) signaling is involved in phagocytosis activation during THP-1 cell differentiation. J Vet Med Sci. (2023) 85:772–80. doi: 10.1292/jvms.22-0504
17. Erra Diaz F, Mazzitelli I, Bleichmar L, Melucci C, Thibodeau A, Dalotto Moreno T, et al. Concomitant inhibition of PPARγ and mTORC1 induces the differentiation of human monocytes into highly immunogenic dendritic cells. Cell Rep. (2023) 42:112156. doi: 10.1016/j.celrep.2023.112156
18. Brombacher EC, Patente TA, van der Ham AJ, Moll TJA, Otto F, Verheijen FWM, et al. AMPK activation induces RALDH+ tolerogenic dendritic cells by rewiring glucose and lipid metabolism. J Cell Biol. (2024) 223(10). doi: 10.1083/jcb.202401024
19. Wculek SK, Heras-Murillo I, Mastrangelo A, Mañanes D, Galán M, Miguel V, et al. Oxidative phosphorylation selectively orchestrates tissue macrophage homeostasis. Immunity. (2023) 56:516–30.e9. doi: 10.1016/j.immuni.2023.01.011
20. Cox DJ, Connolly SA C, Brugman AAI, Sandby Thomas O, Duffin E, et al. Human airway macrophages are metabolically reprogrammed by IFN-γ resulting in glycolysis-dependent functional plasticity. Elife. (2024) 13. doi: 10.7554/eLife.98449
21. Vigeland CL, Link JD, Beggs HS, Alwarawrah Y, Ehrmann BM, Dang H, et al. Alveolar and Bone Marrow-derived Macrophages Differ in Metabolism and Glutamine Utilization. Am J Respir Cell Mol Biol. (2025) 72:563–77. doi: 10.1165/rcmb.2023-0249OC
22. Li R, Lei Y, Rezk A, Diego AE, Wang J, Feng H, et al. Oxidative phosphorylation regulates B cell effector cytokines and promotes inflammation in multiple sclerosis. Sci Immunol. (2024). doi: 10.1126/sciimmunol.adk0865
23. Mittal R, Lemos JRN, Chapagain P, and Hirani K. Interplay of hypoxia, immune dysregulation, and metabolic stress in pathophysiology of type 1 diabetes. Front Immunol. (2025) 16:1599321. doi: 10.3389/fimmu.2025.1599321
24. Maestas MM, Ishahak M, Augsornworawat P, Veronese-Paniagua DA, Maxwell KG, Velazco-Cruz L, et al. Identification of unique cell type responses in pancreatic islets to stress. Nat Commun. (2024) 15:5567. doi: 10.1038/s41467-024-49724-w
25. Stancill JS, Kasmani MY, Cui W, and Corbett JA. Single Cell RNAseq Analysis of Cytokine-Treated Human Islets: Association of Cellular Stress with Impaired Cytokine Responsiveness. Funct (Oxf). (2024) 5(4). doi: 10.1093/function/zqae015
26. Zavarzadeh PG, Panchal K, Bishop D, Gilbert E, Trivedi M, Kee T, et al. Exploring proinsulin proteostasis: insights into beta cell health and diabetes. Front Mol Biosci. (2025) 12:1554717. doi: 10.3389/fmolb.2025.1554717
27. Diane A, Allouch A, Mu UMRBA, and Al-Siddiqi HH. Endoplasmic reticulum stress in pancreatic β-cell dysfunctionality and diabetes mellitus: a promising target for generation of functional hPSC-derived β-cells in vitro. Front Endocrinol (Lausanne). (2024) 15:1386471. doi: 10.3389/fendo.2024.1386471
28. Chen X, Shi C, He M, Xiong S, and Xia X. Endoplasmic reticulum stress: molecular mechanism and therapeutic targets. Signal Transduct Target Ther. (2023) 8:352. doi: 10.1038/s41392-023-01570-w
29. Zhang W and Cao X. Unfolded protein responses in T cell immunity. Front Immunol. (2024) 15:1515715. doi: 10.3389/fimmu.2024.1515715
30. Mbara KC, Fotsing MCD, Ndinteh DT, Mbeb CN, Nwagwu CS, Khan R, et al. Endoplasmic reticulum stress in pancreatic β-cell dysfunction: The potential therapeutic role of dietary flavonoids. Curr Res Pharmacol Drug Discovery. (2024) 6:100184. doi: 10.1016/j.crphar.2024.100184
31. Dettmer R, Niwolik I, Cirksena K, Yoshimoto T, Tang Y, Mehmeti I, et al. Proinflammatory cytokines induce rapid, NO-independent apoptosis, expression of chemotactic mediators and interleukin-32 secretion in human pluripotent stem cell-derived beta cells. Diabetologia. (2022) 65:829–43. doi: 10.1007/s00125-022-05654-0
32. Zhang Y, Lin S, Yao J, Cai W, Chen H, Aierken A, et al. XBP1 splicing contributes to endoplasmic reticulum stress-induced human islet amyloid polypeptide up-regulation. Genes Dis. (2024) 11:101148. doi: 10.1016/j.gendis.2023.101148
33. Lee K, Chan JY, Liang C, Ip CK, Shi YC, Herzog H, et al. XBP1 maintains beta cell identity, represses beta-to-alpha cell transdifferentiation and protects against diabetic beta cell failure during metabolic stress in mice. Diabetologia. (2022) 65:984–96. doi: 10.1007/s00125-022-05669-7
34. Amiri M, Kiniry SJ, Possemato AP, Mahmood N, Basiri T, Dufour CR, et al. Impact of eIF2α phosphorylation on the translational landscape of mouse embryonic stem cells. Cell Rep. (2024) 43:113615. doi: 10.1016/j.celrep.2023.113615
35. Coomans de Brachène A, Alvelos MI, Szymczak F, Zimath PL, Castela A, Marmontel de Souza B, et al. Interferons are key cytokines acting on pancreatic islets in type 1 diabetes. Diabetologia. (2024) 67:908–27. doi: 10.1007/s00125-024-06106-7
36. Dhayal S, Leslie KA, Baity M, Akhbari P, Richardson SJ, Russell MA, et al. Temporal regulation of interferon signalling in human EndoC-βH1 cells. J Mol Endocrinol. (2022) 69:299–313. doi: 10.1530/jme-21-0224
37. Szymczak F, Alvelos MI, Marín-Cañas S, Castela Â, Demine S, Colli ML, et al. Transcription and splicing regulation by NLRC5 shape the interferon response in human pancreatic β cells. Sci Adv. (2022). doi: 10.1126/sciadv.abn5732
38. Nanaware PP, Calvo-Calle JM, Redick SD, Tarpley MW, Cruz J, Clement CC, et al. The antigen presentation landscape of cytokine-stressed human pancreatic islets. Cell Rep. (2025) 44:115927. doi: 10.1016/j.celrep.2025.115927
39. Apaolaza PS, Balcacean D, Zapardiel-Gonzalo J, Nelson G, Lenchik N, Akhbari P, et al. Islet expression of type I interferon response sensors is associated with immune infiltration and viral infection in type 1 diabetes. Sci Adv. (2021) 7(9). doi: 10.1126/sciadv.abd6527
40. Tappe C, Parambath M, Reschke J, and Rustenbeck I. The Amount of Releasable Insulin Depends on Continuous Oxidative Phosphorylation. Funct (Oxf). (2025) 6(5). doi: 10.1093/function/zqaf033
41. Stoolman JS, Grant RA, Billingham LK, Poor TA, Weinberg SE, Harding MC, et al. Mitochondria complex III-generated superoxide is essential for IL-10 secretion in macrophages. Sci Adv. (2025). doi: 10.1126/sciadv.adu4369
42. Yang ML, Connolly SE, Gee RJ, Lam TT, Kanyo J, Peng J, et al. Carbonyl Posttranslational Modification Associated With Early-Onset Type 1 Diabetes Autoimmunity. Diabetes. (2022) 71:1979–93. doi: 10.2337/db21-0989
43. Strollo R, Vinci C, Arshad MH, Perrett D, Tiberti C, Chiarelli F, et al. Antibodies to post-translationally modified insulin in type 1 diabetes. Diabetologia. (2015) 58:2851–60. doi: 10.1007/s00125-015-3746-x
44. Strollo R, Vinci C, Man YKS, Bruzzaniti S, Piemonte E, Alhamar G, et al. Autoantibody and T cell responses to oxidative post-translationally modified insulin neoantigenic peptides in type 1 diabetes. Diabetologia. (2023) 66:132–46. doi: 10.1007/s00125-022-05812-4
45. Arunagiri A, Haataja L, Cunningham CN, Shrestha N, Tsai B, Qi L, et al. Misfolded proinsulin in the endoplasmic reticulum during development of beta cell failure in diabetes. Ann N Y Acad Sci. (2018) 1418:5–19. doi: 10.1111/nyas.13531
46. Haataja L, Manickam N, Soliman A, Tsai B, Liu M, and Arvan P. Disulfide Mispairing During Proinsulin Folding in the Endoplasmic Reticulum. Diabetes. (2016) 65:1050–60. doi: 10.2337/db15-1345
47. Sun J, Cui J, He Q, Chen Z, Arvan P, and Liu M. Proinsulin misfolding and endoplasmic reticulum stress during the development and progression of diabetes. Mol Aspects Med. (2015) 42:105–18. doi: 10.1016/j.mam.2015.01.001
48. Trujillo JA, Croft NP, Dudek NL, Channappanavar R, Theodossis A, Webb AI, et al. The cellular redox environment alters antigen presentation. J Biol Chem. (2014) 289:27979–91. doi: 10.1074/jbc.M114.573402
49. Liepe J, Marino F, Sidney J, Jeko A, Bunting DE, Sette A, et al. A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science. (2016) 354:354–8. doi: 10.1126/science.aaf4384
50. Lai P, Liu L, Bancaro N, Troiani M, Calì B, Li Y, et al. Mitochondrial DNA released by senescent tumor cells enhances PMN-MDSC-driven immunosuppression through the cGAS-STING pathway. Immunity. (2025) 58:811–25.e7. doi: 10.1016/j.immuni.2025.03.005
51. Pizzuto M, Monteleone M, Burgener SS, Began J, Kurera M, Chia JR, et al. Cardiolipin inhibits the non-canonical inflammasome by preventing LPS binding to caspase-4/11. EMBO J. (2025) 44:4419–42. doi: 10.1038/s44318-025-00507-z
52. Liu DH, Li F, Yang RZ, Wu Z, Meng XY, Li SM, et al. Pulmonary mitochondrial DNA release and activation of the cGAS-STING pathway in Lethal Stx12 knockout mice. Cell Commun Signal. (2025) 23:174. doi: 10.1186/s12964-025-02141-y
53. Piganelli JD, Mamula MJ, and James EA. The Role of β Cell Stress and Neo-Epitopes in the Immunopathology of Type 1 Diabetes. Front Endocrinol (Lausanne). (2020) 11:624590. doi: 10.3389/fendo.2020.624590
54. Zhai Y, Chen L, Zhao Q, Zheng ZH, Chen ZN, Bian H, et al. Cysteine carboxyethylation generates neoantigens to induce HLA-restricted autoimmunity. Science. (2023) 379:eabg2482. doi: 10.1126/science.abg2482
55. Groegler J, Mangold K, Nicholson K, Dang M, Wenzlau J, Beard KS, et al. Strategic Reduction of Hybrid Insulin Peptide Formation Significantly Delays Diabetes Onset in NOD Mice. Diabetes. (2025). doi: 10.2337/db25-0324
56. Hohenstein AC, Gallegos JB, Dang M, Groegler J, Broncucia H, Tensun FA, et al. Novel T-Cell Reactivities to Hybrid Insulin Peptides in Islet Autoantibody-Positive At-Risk Individuals. Diabetes. (2025) 74:933–42. doi: 10.2337/db24-0611
57. Wenzlau JM, Peterson OJ, Vomund AN, DiLisio JE, Hohenstein A, Haskins K, et al. Mapping of a hybrid insulin peptide in the inflamed islet β-cells from NOD mice. Front Immunol. (2024) 15:1348131. doi: 10.3389/fimmu.2024.1348131
58. Usatiuc LO, Pop RM, Adrian S, Pârvu M, Nicolea M, Uifălean A, et al. Multitargeted Effects of Plantago ovata Ethanol Extract in Experimental Rat Streptozotocin-Induced Diabetes Mellitus and Letrozole-Induced Polycystic Ovary Syndrome. Int J Mol Sci. (2025) 26(10). doi: 10.3390/ijms26104712
59. Dudek NL, Tan CT, Gorasia DG, Croft NP, Illing PT, and Purcell AW. Constitutive and inflammatory immunopeptidome of pancreatic β-cells. Diabetes. (2012) 61:3018–25. doi: 10.2337/db11-1333
60. Ott C, Tomasina F, Campolo N, Bartesaghi S, Mastrogiovanni M, Leyva A, et al. Decreased proteasomal cleavage at nitrotyrosine sites in proteins and peptides. Redox Biol. (2021) 46:102106. doi: 10.1016/j.redox.2021.102106
61. Hardy LL, Wick DA, and Webb JR. Conversion of tyrosine to the inflammation-associated analog 3'-nitrotyrosine at either TCR- or MHC-contact positions can profoundly affect recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis virus glycoprotein 33 by CD8 T cells. J Immunol. (2008) 180:5956–62. doi: 10.4049/jimmunol.180.9.5956
62. van Lummel M, Duinkerken G, van Veelen PA, de Ru A, Cordfunke R, Zaldumbide A, et al. Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes. (2014) 63:237–47. doi: 10.2337/db12-1214
63. Gonzalez-Duque S, Azoury ME, Colli ML, Afonso G, Turatsinze JV, Nigi L, et al. Conventional and Neo-antigenic Peptides Presented by β Cells Are Targeted by Circulating Naïve CD8+ T Cells in Type 1 Diabetic and Healthy Donors. Cell Metab. (2018) 28:946–60.e6. doi: 10.1016/j.cmet.2018.07.007
64. Wiles TA, Powell R, Michel R, Beard KS, Hohenstein A, Bradley B, et al. Identification of Hybrid Insulin Peptides (HIPs) in Mouse and Human Islets by Mass Spectrometry. J Proteome Res. (2019) 18:814–25. doi: 10.1021/acs.jproteome.8b00875
65. Srivastava N, Vomund AN, Yu R, Peterson OJ, Yang Y, Turicek DP, et al. A microenvironment-driven HLA-II-associated insulin neoantigen elicits persistent memory T cell activation in diabetes. Nat Immunol. (2025). doi: 10.1038/s41590-025-02343-z
66. Rodriguez-Calvo T, Johnson JD, Overbergh L, and Dunne JL. Neoepitopes in Type 1 Diabetes: Etiological Insights, Biomarkers and Therapeutic Targets. Front Immunol. (2021) 12:667989. doi: 10.3389/fimmu.2021.667989
67. Balakrishnan S, Kumar P, and Prabhakar BS. Post-translational modifications contribute to neoepitopes in Type-1 diabetes: Challenges for inducing antigen-specific tolerance. Biochim Biophys Acta Proteins Proteom. (2020) 1868:140478. doi: 10.1016/j.bbapap.2020.140478
68. Hecker M and Wagner AH. Role of protein carbonylation in diabetes. J Inherit Metab Dis. (2018) 41:29–38. doi: 10.1007/s10545-017-0104-9
69. Saunders EF, Schultz KR, Lowe I, Anderson AL, Bikkumalla VS, Soto D, et al. Rapid protein carbonylation and decreased insulin secretion induced by inflammatory oxidative stress compounds. Free Radic Biol Med. (2025) 242:320–32. doi: 10.1016/j.freeradbiomed.2025.10.299
70. Moon JS, Younis S, Ramadoss NS, Iyer R, Sheth K, Sharpe O, et al. Cytotoxic CD8(+) T cells target citrullinated antigens in rheumatoid arthritis. Nat Commun. (2023) 14:319. doi: 10.1038/s41467-022-35264-8
71. Curran AM, Girgis AA, Jang Y, Crawford JD, Thomas MA, Kawalerski R, et al. Citrullination modulates antigen processing and presentation by revealing cryptic epitopes in rheumatoid arthritis. Nat Commun. (2023) 14:1061. doi: 10.1038/s41467-023-36620-y
72. Yu K, Dillemans L, Gouwy M, Bessa H, Metzemaekers M, Martens E, et al. Novel method to quantify peptidylarginine deiminase activity shows distinct citrullination patterns in rheumatoid and juvenile idiopathic arthritis. Front Immunol. (2023) 14:1111465. doi: 10.3389/fimmu.2023.1111465
73. Kang HL, Szász A, Valkusz Z, Várkonyi T, Pósa A, and Kupai K. Targeting PAD4: A Promising Strategy to Combat β-Cell Loss in Type 1 Diabetes. Int J Mol Sci. (2025) 26(13). doi: 10.3390/ijms26136113
74. Roy S, Pokharel P, and Piganelli JD. Decoding the immune dance: Unraveling the interplay between beta cells and type 1 diabetes. Mol Metab. (2024) 88:101998. doi: 10.1016/j.molmet.2024.101998
75. Pach N and Basler M. Cellular stress increases DRIP production and MHC Class I antigen presentation. Front Immunol. (2024) 15:1445338. doi: 10.3389/fimmu.2024.1445338
76. Rodriguez-Calvo T, Laiho JE, Oikarinen M, Akhbari P, Flaxman C, Worthington T, et al. Enterovirus VP1 protein and HLA class I hyperexpression in pancreatic islet cells of organ donors with type 1 diabetes. Diabetologia. (2025) 68:1197–210. doi: 10.1007/s00125-025-06384-9
77. Huber MK, Widener AE, Cuaycal AE, Smurlick D, Butterworth EA, Lenchik NI, et al. Beta cell dysfunction occurs independently of insulitis in type 1 diabetes pathogenesis. Cell Rep. (2025) 44:116174. doi: 10.1016/j.celrep.2025.116174
78. Akhbari P, Perez-Hernandez J, Russell MA, Dhayal S, Leslie KA, Hunter SL, et al. Soluble HLA Class I Is Released From Human β-Cells Following Exposure to Interferons. Diabetes. (2025) 74:956–68. doi: 10.2337/db24-0827
79. Swensen AC, Piehowski PD, Chen J, Chan XY, Kelly SS, Petyuk VA, et al. Increased inflammation as well as decreased endoplasmic reticulum stress and translation differentiate pancreatic islets from donors with pre-symptomatic stage 1 type 1 diabetes and non-diabetic donors. Diabetologia. (2025) 68:1463–75. doi: 10.1007/s00125-025-06417-3
80. Johansen CG, Lam K, and Farnsworth NL. Stressed β-cells contribute to loss of peri-islet extracellular matrix in type 1 diabetes. Front Endocrinol (Lausanne). (2025) 16:1675043. doi: 10.3389/fendo.2025.1675043
81. Syed F, Ballew O, Lee CC, Rana J, Krishnan P, Castela A, et al. Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice. EBioMedicine. (2025) 117:105734. doi: 10.1016/j.ebiom.2025.105734
82. Thielert M, Villalba A, Brennsteiner V, Wahle M, Ammar C, Brunner AD, et al. Decoding adult murine pancreatic islet cell diversity through cell type-resolved proteomics and phosphoproteomics. Commun Biol. (2025) 8:1483. doi: 10.1038/s42003-025-08918-8
83. Darley R, Illing PT, Duriez P, Bailey A, Purcell AW, van Hateren A, et al. Evidence of focusing the MHC class I immunopeptidome by tapasin. Front Immunol. (2025) 16:1563789. doi: 10.3389/fimmu.2025.1563789
84. Chen Y, Shen M, Gu Y, Xu X, Bian L, Yang F, et al. Pivotal epitopes for islet antigen-specific CD8(+) T cell detection improve classification of suspected type 1 diabetes with the HLA-A*0201 allele. Immunol Res. (2025) 73:65. doi: 10.1007/s12026-025-09616-7
85. Su Z, Bian L, Zhao H, Cai Y, Yang T, Li S, et al. Gut-tropic α4β7(+)CD8(+) T cells contribute to pancreatic β cell destruction in type 1 diabetes. Front Immunol. (2025) 16:1623428. doi: 10.3389/fimmu.2025.1623428
86. Barlow GL, Schürch CM, Bhate SS, Phillips DJ, Young A, Dong S, et al. The extra-islet pancreas supports autoimmunity in human type 1 diabetes. Elife. (2025) 13. doi: 10.7554/eLife.100535
87. Golden GJ, Wu VH, Hamilton JT, Amses KR, Shapiro MR, Sada Japp A, et al. Immune perturbations in human pancreas lymphatic tissues prior to and after type 1 diabetes onset. Nat Commun. (2025) 16:4621. doi: 10.1038/s41467-025-59626-0
88. Zhang Y, Hong S, Zhang F, Yao K, Jin S, Gao S, et al. Immunoproteasome subunit PSMB8 promotes skeletal muscle regeneration by regulating macrophage phenotyping switch in mice. Am J Physiol Cell Physiol. (2025) 328:C1716–c29. doi: 10.1152/ajpcell.00965.2024
89. Lu R, Abuduhailili X, Li Y, Wang S, Xia X, and Feng Y. Integrated Analysis of PSMB8 Expression and Its Potential Roles in Hepatocellular Carcinoma. Dig Dis Sci. (2025) 70:2719–38. doi: 10.1007/s10620-025-09040-9
90. Ives AN, Sagendorf TJ, Nierves L, Lin TT, Dirice E, Kulkarni RN, et al. Characterization of Cytokine Treatment on Human Pancreatic Islets by Top-Down Proteomics. Proteomics. 2025:e70044. doi: 10.1002/pmic.70044
91. Losier TT, King KE, Rousseaux MWC, and Russell RC. Identification of organelle-specific autophagy regulators from tandem CRISPR screens. J Cell Biol. (2025) 224(10). doi: 10.1083/jcb.202405138
92. Jin M and Klionsky DJ. Nuclear proteasomes as a backup for autophagy: interconnected proteostasis pathways. Autophagy. (2025) 21:1–2. doi: 10.1080/15548627.2024.2416261
93. Yamashita SI, Arai R, Hada H, Padman BS, Lazarou M, Chan DC, et al. The mitophagy receptors BNIP3 and NIX mediate tight attachment and expansion of the isolation membrane to mitochondria. J Cell Biol. (2025), 224(7). doi: 10.1083/jcb.202408166
94. Shrestha N, Torres M, Zhang J, Lu Y, Haataja L, Reinert RB, et al. Integration of ER protein quality control mechanisms defines β cell function and ER architecture. J Clin Invest. (2023), 133(1). doi: 10.1172/jci163584
95. Carroll DT, Miller A, Fuhr J, Elsakr JM, Ricciardi V, Del Bene AN, et al. Analysis of beta-cell maturity and mitochondrial morphology in juvenile non-human primates exposed to maternal Western-style diet during development. Front Endocrinol (Lausanne). (2024) 15:1417437. doi: 10.3389/fendo.2024.1417437
96. Xian J, Gao L, Ren Z, Jiang Y, Pan J, Ying Z, et al. Inhibition of Autophagy by Berbamine Hydrochloride Mitigates Tumor Immune Escape by Elevating MHC-I in Melanoma Cells. Cells. (2024), 13(18). doi: 10.3390/cells13181537
97. Luo H, Chen D, Zhou J, Wang D, Du Q, Cai Q, et al. Cepharanthine Enhances MHC-I Antigen Presentation and Anti-Tumor Immunity in Melanoma via Autophagy Inhibition. Cells. (2025), 14(16). doi: 10.3390/cells14161231
98. Estephan H, Tailor A, Parker R, Kreamer M, Papandreou I, Campo L, et al. Hypoxia promotes tumor immune evasion by suppressing MHC-I expression and antigen presentation. EMBO J. (2025) 44:903–22. doi: 10.1038/s44318-024-00319-7
99. Peddaboina C, Iannucci J, Tobin RP, Shapiro LA, and Newell Rogers MK. Autophagy Differentially Influences Toll-like Receptor 9 and B Cell-Receptor-Mediated B Cell Expansion, Expression of Major Histocompatibility Class II Proteins, and Antigenic Peptide Presentation. Int J Mol Sci. (2025), 26(13). doi: 10.3390/ijms26136054
100. Jiménez-Loygorri JI, Villarejo-Zori B, Viedma-Poyatos Á, Zapata-Muñoz J, Benítez-Fernández R, Frutos-Lisón MD, et al. Mitophagy curtails cytosolic mtDNA-dependent activation of cGAS/STING inflammation during aging. Nat Commun. (2024) 15:830. doi: 10.1038/s41467-024-45044-1
101. Ji Y, Ma Y, Ma Y, Wang Y, Zhao X, Jin D, et al. SS-31 inhibits mtDNA-cGAS-STING signaling to improve POCD by activating mitophagy in aged mice. Inflammation Res. (2024) 73:641–54. doi: 10.1007/s00011-024-01860-1
102. Li C, Zhu Y, Liu W, Xiang W, He S, Hayashi T, et al. Impaired mitophagy causes mitochondrial DNA leakage and STING activation in ultraviolet B-irradiated human keratinocytes HaCaT. Arch Biochem Biophys. (2023) 737:109553. doi: 10.1016/j.abb.2023.109553
103. Sidarala V, Pearson GL, Parekh VS, Thompson B, Christen L, Gingerich MA, et al. Mitophagy protects β cells from inflammatory damage in diabetes. JCI Insight. (2020) 5(24). doi: 10.1172/jci.insight.141138
104. Zhou H, Wang X, Xu T, Gan D, Ma Z, Zhang H, et al. PINK1-mediated mitophagy attenuates pathological cardiac hypertrophy by suppressing the mtDNA release-activated cGAS-STING pathway. Cardiovasc Res. (2025) 121:128–42. doi: 10.1093/cvr/cvae238
105. Jiang C, Li Y, Duan K, Zhan T, Chen Z, Wang Y, et al. Parkin deletion affects PINK1/Parkin-mediated mitochondrial autophagy to exacerbate neuroinflammation and accelerate progression of Parkinson's disease in mice. Nan Fang Yi Ke Da Xue Xue Bao. (2024) 44:2359–66. doi: 10.12122/j.issn.1673-4254.2024.12.11
106. VanPortfliet JJ, Chute C, Lei Y, Shutt TE, and West AP. Mitochondrial DNA release and sensing in innate immune responses. Hum Mol Genet. (2024) 33:R80–r91. doi: 10.1093/hmg/ddae031
107. Margaryan S, Poghosyan D, Ghonyan S, Hakobyan L, Martirosyan A, and Manukyan G. Long-term hyperglycaemia exerts contrasting effects on M1- and M2-like macrophages. Front Immunol. (2025) 16:1639650. doi: 10.3389/fimmu.2025.1639650
108. Moeun BN, Lemaire F, Smink AM, Ebrahimi Orimi H, Leask RL, de Vos P, et al. Oxygenation and function of endocrine bioartificial pancreatic tissue constructs under flow for preclinical optimization. J Tissue Eng. (2025) 16:20417314241284826. doi: 10.1177/20417314241284826
109. Pham TT, Tran PL, Tempelman LA, Stone SG, Piccirillo C, Li A, et al. A continuously oxygenated macroencapsulation system enables high-density packing and delivery of insulin-secreting cells. Nat Commun. (2025) 16:7199. doi: 10.1038/s41467-025-62271-2
110. Wang X, Brielle S, Kenty-Ryu J, Korover N, Bavli D, Pop R, et al. Improving cellular fitness of human stem cell-derived islets under hypoxia. Nat Commun. (2025) 16:4787. doi: 10.1038/s41467-025-59924-7
111. Wang JE, Muralidharan C, Puente AA, Nargis T, Enriquez JR, Anderson RM, et al. The integrated stress response promotes macrophage inflammation and migration in autoimmune diabetes. Cell Commun Signal. (2025) 23:374. doi: 10.1186/s12964-025-02372-z
112. Thai LM, O'Reilly L, Reibe-Pal S, Sue N, Holliday H, Small L, et al. [amp]]beta;-cell function is regulated by metabolic and epigenetic programming of islet-associated macrophages, involving Axl, Mertk, and TGFβ receptor signaling. iScience. (2023) 26:106477. doi: 10.1016/j.isci.2023.106477
113. Grosjean A, Jalon A, Leveau C, Diedisheim M, Bejarano DA, Cuenco J, et al. An islet-resident macrophage antioxidant program preserves β cell physiology. Sci Immunol. (2025) 10:eadz5181. doi: 10.1126/sciimmunol.adz5181
114. de Brito Monteiro L, Archambault AS, Soukhatcheva G, Dai D, Velghe J, Chen YC, et al. Assessment of protein synthesis rate enables metabolic profiling of resident-immune cells of the islets of Langerhans. Front Immunol. (2025) 16:1662986. doi: 10.3389/fimmu.2025.1662986
115. Nackiewicz D, Dan M, Speck M, Chow SZ, Chen YC, Pospisilik JA, et al. Islet Macrophages Shift to a Reparative State following Pancreatic Beta-Cell Death and Are a Major Source of Islet Insulin-like Growth Factor-1. iScience. (2020) 23:100775. doi: 10.1016/j.isci.2019.100775
116. Davanso MR, Crisma AR, Braga TT, Masi LN, do Amaral CL, Leal VNC, et al. Macrophage inflammatory state in Type 1 diabetes: triggered by NLRP3/iNOS pathway and attenuated by docosahexaenoic acid. Clin Sci (Lond). (2021) 135:19–34. doi: 10.1042/cs20201348
117. Hu Z, Yu X, Ding R, Liu B, Gu C, Pan XW, et al. Glycolysis drives STING signaling to facilitate dendritic cell antitumor function. J Clin Invest. (2023) 133(7). doi: 10.1172/jci166031
118. Zakharov PN, Hu H, Wan X, and Unanue ER. Single-cell RNA sequencing of murine islets shows high cellular complexity at all stages of autoimmune diabetes. J Exp Med. (2020), 217(6). doi: 10.1084/jem.20192362
119. Weber S, Wei X, Chen G, Yankouskaya K, Yin D, Allabauer I, et al. Pharmacodynamic effect of mTOR inhibition-based immunosuppressive therapy on dendritic cell and natural killer cell subsets after renal transplantation. Clin Exp Immunol. (2025), 219(1). doi: 10.1093/cei/uxaf026
120. Sanlorenzo M, Novoszel P, Vujic I, Gastaldi T, Hammer M, Fari O, et al. Systemic IFN-I combined with topical TLR7/8 agonists promotes distant tumor suppression by c-Jun-dependent IL-12 expression in dendritic cells. Nat Cancer. (2025) 6:175–93. doi: 10.1038/s43018-024-00889-9
121. Tang Q, Fan G, Peng X, Sun X, Kong X, Zhang L, et al. Gut bacterial L-lysine alters metabolism and histone methylation to drive dendritic cell tolerance. Cell Rep. (2025) 44:115125. doi: 10.1016/j.celrep.2024.115125
122. Jia Y, Li R, Huang L, Wu X, Zhao L, Yang H, et al. The Glycolysis-HIF-1α axis induces IL-1β of macrophages in rheumatoid arthritis. Arthritis Res Ther. (2025) 27:180. doi: 10.1186/s13075-025-03647-z
123. Sun Y, Lou F, Cai X, Wang Z, Yang X, Sun L, et al. CCR7(+) dendritic cells expressing both IL-23A and IL-12B potentially contribute to psoriasis relapse. Nat Commun. (2025) 16:7581. doi: 10.1038/s41467-025-62874-9
124. Chen J, Tan Q, Yang Z, Chen W, Zhou E, Li M, et al. Dendritic Cell Derived-Extracellular Vesicles Engineered to Express Interleukin-12 and Anti-CTLA-4 on Their Surface for Combinational Cancer Immunotherapy. J Extracell Vesicles. (2025) 14:e70068. doi: 10.1002/jev2.70068
125. Ghasemi A, Martinez-Usatorre A, Liu Y, Demagny H, Li L, Mohammadzadeh Y, et al. Dendritic cell progenitors engineered to express extracellular-vesicle-internalizing receptors enhance cancer immunotherapy in mouse models. Nat Commun. (2025) 16:9148. doi: 10.1038/s41467-025-64172-w
126. Carvalho G, Nguyen TVH, Repolês B, Forslund JME, Wijethunga W, Ranjbarian F, et al. Activating AMPK improves pathological phenotypes due to mtDNA depletion. FEBS J. (2025) 292:2359–80. doi: 10.1111/febs.70006
127. Suzuki H, Hasegawa S, Fushimi S, Tagami K, Nishikawa M, Kondo Y, et al. Metformin prevents diabetes development in type 1 diabetes models via suppression of mTOR and STAT3 signaling in immune cells. Sci Rep. (2025) 15:10641. doi: 10.1038/s41598-025-93647-5
128. Huang D, Li Q, Peng S, Li Y, Yin Q, Yang X, et al. GCN2-Mediated Integrated Stress Response Attenuates Periodontitis. J Dent Res. 2025:220345251363525. doi: 10.1177/00220345251363525
129. Worpenberg L, Gobet C, and Naef F. Codon-specific ribosome stalling reshapes translational dynamics during branched-chain amino acid starvation. Genome Biol. (2025) 26:315. doi: 10.1186/s13059-025-03800-6
130. Russier M, Fiore A, Bici A, Groß A, Tanzer M, Yeroslaviz A, et al. Differential cell survival outcomes in response to diverse amino acid stress. Life Sci Alliance. (2025), 8(11). doi: 10.26508/lsa.202503324
131. You Z and Chi H. Lipid metabolism in dendritic cell biology. Immunol Rev. (2023) 317:137–51. doi: 10.1111/imr.13215
132. Hildreth AD, Padilla ET, Gupta M, Wong YY, Sun R, Legala AR, et al. Adipose cDC1s contribute to obesity-associated inflammation through STING-dependent IL-12 production. Nat Metab. (2023) 5:2237–52. doi: 10.1038/s42255-023-00934-4
133. Huang S, Shahine A, Cheng TY, Chen YL, Ng SW, Balaji GR, et al. CD1 lipidomes reveal lipid-binding motifs and size-based antigen-display mechanisms. Cell. (2023) 186:4583–96.e13. doi: 10.1016/j.cell.2023.08.022
134. Mandal M, Mamun MAA, Rakib A, and Singh UP. High-fat diet-induced adipose tissue-resident macrophages, T cells, and dendritic cells modulate chronic inflammation and adipogenesis during obesity. Front Immunol. (2025) 16:1524544. doi: 10.3389/fimmu.2025.1524544
135. Peng W, Chen S, Ma J, Wei W, Lin N, Xing J, et al. Endosomal trafficking participates in lipid droplet catabolism to maintain lipid homeostasis. Nat Commun. (2025) 16:1917. doi: 10.1038/s41467-025-57038-8
136. Beretta C, Dakhel A, Eltom K, Rosqvist F, Uzoni S, Mothes T, et al. Astrocytic lipid droplets contain MHCII and may act as cogs in the antigen presentation machinery. J Neuroinflammation. (2025) 22:117. doi: 10.1186/s12974-025-03452-0
137. Barends M, Koller N, Schölz C, Durán V, Bošnjak B, Becker J, et al. Dynamic interactome of the MHC I peptide loading complex in human dendritic cells. Proc Natl Acad Sci U S A. (2023) 120:e2219790120. doi: 10.1073/pnas.2219790120
138. Fujioka Y, Ueki H AR, Sasajima A, Tomono T, Ukawa M, et al. The Improved Antigen Uptake and Presentation of Dendritic Cells Using Cell-Penetrating D-octaarginine-Linked PNVA-co-AA as a Novel Dendritic Cell-Based Vaccine. Int J Mol Sci. (2024), 25(11). doi: 10.3390/ijms25115997
139. Wong A, Sun Q, Latif II, and Karwi QG. Metabolic flux in macrophages in obesity and type-2 diabetes. J Pharm Pharm Sci. (2024) 27:13210. doi: 10.3389/jpps.2024.13210
140. Srivastava N, Hu H, Peterson OJ, Vomund AN, Stremska M, Zaman M, et al. CXCL16-dependent scavenging of oxidized lipids by islet macrophages promotes differentiation of pathogenic CD8(+) T cells in diabetic autoimmunity. Immunity. (2024) 57:1629–47.e8. doi: 10.1016/j.immuni.2024.04.017
141. Zhang D, Meng L, Xi M, Li S, Chen W, Li L, et al. Interactions between islet-resident macrophages and β cells in diabetes. Front Immunol. (2025) 16:1630507. doi: 10.3389/fimmu.2025.1630507
142. Ramakrishnan R, Tyurin VA, Veglia F, Condamine T, Amoscato A, Mohammadyani D, et al. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol. (2014) 192:2920–31. doi: 10.4049/jimmunol.1302801
143. Evans L and Barral P. CD1 molecules: Beyond antigen presentation. Mol Immunol. (2024) 170:1–8. doi: 10.1016/j.molimm.2024.03.011
144. Wang Y, Zou Y, Jiang Q, Li W, Chai X, Zhao T, et al. Ox-LDL-induced CD80(+) macrophages expand pro-atherosclerotic NKT cells via CD1d in atherosclerotic mice and hyperlipidemic patients. Am J Physiol Cell Physiol. (2024). doi: 10.1152/ajpcell.00043.2024
145. Kumar V, Hertz M, Agro A, and Byrne AJ. Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis. Front Immunol. (2023) 14:1260503. doi: 10.3389/fimmu.2023.1260503
146. Starskaia I, Valta M, Pietilä S, Suomi T, Pahkuri S, Kalim UU, et al. Distinct cellular immune responses in children en route to type 1 diabetes with different first-appearing autoantibodies. Nat Commun. (2024) 15:3810. doi: 10.1038/s41467-024-47918-w
147. Milkovic L, Zarkovic N, Marusic Z, Zarkovic K, and Jaganjac M. The 4-Hydroxynonenal-Protein Adducts and Their Biological Relevance: Are Some Proteins Preferred Targets? Antioxidants (Basel). (2023), 12(4). doi: 10.3390/antiox12040856
148. Ioannidis M, Tjepkema J, Uitbeijerse MRP, and van den Bogaart G. Immunomodulatory effects of 4-hydroxynonenal. Redox Biol. (2025) 85:103719. doi: 10.1016/j.redox.2025.103719
149. Hsu CG, Chávez CL, Zhang C, Sowden M, Yan C, and Berk BC. The lipid peroxidation product 4-hydroxynonenal inhibits NLRP3 inflammasome activation and macrophage pyroptosis. Cell Death Differ. (2022) 29:1790–803. doi: 10.1038/s41418-022-00966-5
150. Guo J, Dai B, Zhu H, Sui C, Dong Z, Chen K, et al. APOA2 mediates immune therapy tolerance in hepatocellular carcinoma by inhibiting the antigen-presenting function of dendritic cells through the PPAR signaling pathway. Transl Cancer Res. (2025) 14:5777–91. doi: 10.21037/tcr-2025-321
151. John SV, Seim GL, Erazo-Flores BJ, Votava JA, Urquiza US, Arp NL, et al. Classically activated macrophages undergo functionally significant nucleotide metabolism remodelling driven by nitric oxide. Nat Metab. (2025) 7:1681–702. doi: 10.1038/s42255-025-01337-3
152. Fabrik I, Spidlova P, Prchal L, Fabrikova D, Viduka I, Marecic V, et al. Glutamate utilization fuels rapid production of mitochondrial ROS in dendritic cells and drives systemic inflammation during tularemia. Sci Adv. (2025) 11:eadu6271. doi: 10.1126/sciadv.adu6271
153. López Malizia A, Merlotti A, Bonte PE, Sager M, Arribas De Sandoval Y, Goudot C, et al. Clusterin protects mature dendritic cells from reactive oxygen species mediated cell death. Oncoimmunology. (2024) 13:2294564. doi: 10.1080/2162402x.2023.2294564
154. Wang Q, Yin X, Huang X, Zhang L, and Lu H. Impact of mitochondrial dysfunction on the antitumor effects of immune cells. Front Immunol. (2024) 15:1428596. doi: 10.3389/fimmu.2024.1428596
155. Zhang T, Wei X, Li Y, Huang S, Wu Y, Cai S, et al. Dendritic cell-based vaccine prepared with recombinant Lactococcus lactis enhances antigen cross-presentation and antitumor efficacy through ROS production. Front Immunol. (2023) 14:1208349. doi: 10.3389/fimmu.2023.1208349
156. Moussion C and Delamarre L. Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy. Semin Immunol. (2024) 71:101848. doi: 10.1016/j.smim.2023.101848
157. Kelly JJ, Bloodworth N, Shao Q, Shabanowitz J, Hunt D, Meiler J, et al. A Chemical Approach to Assess the Impact of Post-translational Modification on MHC Peptide Binding and Effector Cell Engagement. ACS Chem Biol. (2024) 19:1991–2001. doi: 10.1021/acschembio.4c00312
158. Mahoney KE, Reser L, Ruiz Cuevas MV, Abelin JG, Shabanowitz J, Hunt DF, et al. Identification of Post-translationally Modified MHC Class I-Associated Peptides as Potential Cancer Immunotherapeutic Targets. Mol Cell Proteomics. (2025) 24:100971. doi: 10.1016/j.mcpro.2025.100971
159. Bruno PM, Timms RT, Abdelfattah NS, Leng Y, Lelis FJN, Wesemann DR, et al. High-throughput, targeted MHC class I immunopeptidomics using a functional genetics screening platform. Nat Biotechnol. (2023) 41:980–92. doi: 10.1038/s41587-022-01566-x
160. Preynat-Seauve O, Coudurier S, Favier A, Marche PN, and Villiers C. Oxidative stress impairs intracellular events involved in antigen processing and presentation to T cells. Cell Stress Chaperones. (2003) 8:162–71. doi: 10.1379/1466-1268(2003)008<0162:osiiei>2.0.co;2
161. Huang H, Li G, He Y, Chen J, Yan J, Zhang Q, et al. Cellular succinate metabolism and signaling in inflammation: implications for therapeutic intervention. Front Immunol. (2024) 15:1404441. doi: 10.3389/fimmu.2024.1404441
162. Xia W, Mao Y, Xia Z, Cheng J, and Jiang P. Metabolic remodelling produces fumarate via the aspartate-argininosuccinate shunt in macrophages as an antiviral defence. Nat Microbiol. (2025) 10:1115–29. doi: 10.1038/s41564-025-01985-x
163. Inamdar S, Suresh AP, Mangal JL, Ng ND, Sundem A, Behbahani HS, et al. Succinate based polymers drive immunometabolism in dendritic cells to generate cancer immunotherapy. J Control Release. (2023) 358:541–54. doi: 10.1016/j.jconrel.2023.05.014
164. Jeridi A, Kapellos TS, and Yildirim A. Fumarate hydratase: a new checkpoint of metabolic regulation in inflammatory macrophages. Signal Transduct Target Ther. (2023) 8:332. doi: 10.1038/s41392-023-01594-2
165. Zhang W and Lang R. Succinate metabolism: a promising therapeutic target for inflammation, ischemia/reperfusion injury and cancer. Front Cell Dev Biol. (2023) 11:1266973. doi: 10.3389/fcell.2023.1266973
166. Xu B, Zhu Z, Shu H, Wang H, Lu X, and Zhu X. Succinate links TCA cycle dysfunction to inflammation by activating HIF-1α signaling in acute kidney injury. Int Immunopharmacol. (2025) 161:115105. doi: 10.1016/j.intimp.2025.115105
167. Dai M, Bu S, and Miao Z. Succinate metabolism: underlying biological mechanisms and emerging therapeutic targets in inflammatory bowel disease. Front Immunol. (2025) 16:1630310. doi: 10.3389/fimmu.2025.1630310
168. Atallah R, Gindlhuber J, and Heinemann A. Succinate in innate immunity: linking metabolic reprogramming to immune modulation. Front Immunol. (2025) 16:1661948. doi: 10.3389/fimmu.2025.1661948
169. Klaimi C, Kong W, Blériot C, and Haas JT. The immunological interface: dendritic cells as key regulators in metabolic dysfunction-associated steatotic liver disease. FEBS Lett. (2025) 599:1971–81. doi: 10.1002/1873-3468.15072
170. Peter A, Vermeulen M, Van Delen M, Dams A, Peeters S, De Reu H, et al. Physiological Oxygen Levels in the Microenvironment Program Ex Vivo-Generated Conventional Dendritic Cells Toward a Tolerogenic Phenotype. Cells. (2025), 14(10). doi: 10.3390/cells14100736
171. Macri C, Jenika D, Ouslinis C, and Mintern JD. Targeting dendritic cells to advance cross-presentation and vaccination outcomes. Semin Immunol. (2023) 68:101762. doi: 10.1016/j.smim.2023.101762
172. Kato H, Salgado M, Mendez D, Gonzalez N, Rawson J, Ligot D, et al. Biological hypoxia in pre-transplant human pancreatic islets induces transplant failure in diabetic mice. Sci Rep. (2024) 14:12402. doi: 10.1038/s41598-024-61604-3
173. Shen H, Ojo OA, Ding H, Mullen LJ, Xing C, Hossain MI, et al. HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells. Nat Commun. (2024) 15:9394. doi: 10.1038/s41467-024-53593-8
174. Raychaudhuri D, Singh P, Chakraborty B, Hennessey M, Tannir AJ, Byregowda S, et al. Histone lactylation drives CD8(+) T cell metabolism and function. Nat Immunol. (2024) 25:2140–51. doi: 10.1038/s41590-024-01985-9
175. Desgeorges T, Galle E, Zhang J, von Meyenn F, and De Bock K. Histone lactylation in macrophages is predictive for gene expression changes during ischemia induced-muscle regeneration. Mol Metab. (2024) 83:101923. doi: 10.1016/j.molmet.2024.101923
176. Zhang Y, Jia P, Wang K, Zhang Y, Lv Y, Fan P, et al. Lactate modulates microglial inflammatory responses after oxygen-glucose deprivation through HIF-1α-mediated inhibition of NF-κB. Brain Res Bull. (2023) 195:1–13. doi: 10.1016/j.brainresbull.2023.02.002
177. Cai Q, Deng W, Zou Y, Chen ZS, and Tang H. Histone lactylation as a driver of metabolic reprogramming and immune evasion. Med Rev (2021). (2025) 5:256–9. doi: 10.1515/mr-2024-0091
178. Llibre A, Kucuk S, Gope A, Certo M, and Mauro C. Lactate: A key regulator of the immune response. Immunity. (2025) 58:535–54. doi: 10.1016/j.immuni.2025.02.008
179. Yuan D, Yang F, Hou L, Zhang Y, Pang X, Du Y, et al. PFKFB2-Driven Glycolysis Promotes Dendritic Cell Maturation and Exacerbates Acute Lung Injury. Adv Sci (Weinh). (2025) 12:e02428. doi: 10.1002/advs.202502428
180. Jiang H, Li Y, Shen M, Liang Y, Qian Y, Dai H, et al. Interferon-α promotes MHC I antigen presentation of islet β cells through STAT1-IRF7 pathway in type 1 diabetes. Immunology. (2022) 166:210–21. doi: 10.1111/imm.13468
181. Groegler J, Callebaut A, James EA, and Delong T. The insulin secretory granule is a hotspot for autoantigen formation in type 1 diabetes. Diabetologia. (2024) 67:1507–16. doi: 10.1007/s00125-024-06164-x
182. Sétula C, Pensado-Evans I, Scelza-Figueredo A, Orellano MS, Rodríguez-Valero I, Spinedi E, et al. IL-1β priming triggers an adaptive stress response that enhances pancreatic β-cell resilience to subsequent cytotoxic inflammatory insult. Cell Death Dis. (2025) 16:744. doi: 10.1038/s41419-025-08059-0
183. Zhang B, Ohuchida K, Tsutsumi C, Shimada Y, Mochida Y, Oyama K, et al. Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. (2024) 43:271. doi: 10.1186/s13046-024-03192-8
184. Gonçalves LM, Shirvaikar I, Sideris K, Pereira E, Slak Rupnik M, and Almaça J. Microvascular Homeostasis Is Compromised in Pancreatic Islets in a Mouse Model of β-Cell Loss and Low-Grade Inflammation. Diabetes. (2025). doi: 10.2337/db25-0368
185. Akhtar MN, Hnatiuk A, Delgadillo-Silva L, Geravandi S, Sameith K, Reinhardt S, et al. Developmental beta-cell death orchestrates the islet's inflammatory milieu by regulating immune system crosstalk. EMBO J. (2025) 44:1131–53. doi: 10.1038/s44318-024-00332-w
186. Pei X, Lu L, Huang Z, Wei Y, Li Y, Wang Q, et al. Activation of M1 macrophages promotes diabetic kidney disease by modulating glycolysis via HIF-1α-HK2 signaling pathway. Diabetol Metab Syndr. (2025) 17:362. doi: 10.1186/s13098-025-01894-3
187. Woods PS and Mutlu GM. Differences in glycolytic metabolism between tissue-resident alveolar macrophages and recruited lung macrophages. Front Immunol. (2025) 16:1535796. doi: 10.3389/fimmu.2025.1535796
188. Labbé K, LeBon L, King B, Vu N, Stoops EH, Ly N, et al. Specific activation of the integrated stress response uncovers regulation of central carbon metabolism and lipid droplet biogenesis. Nat Commun. (2024) 15:8301. doi: 10.1038/s41467-024-52538-5
189. Kim YK, Won KC, and Sussel L. Glucose metabolism partially regulates β-cell function through epigenomic changes. J Diabetes Investig. (2024) 15:649–55. doi: 10.1111/jdi.14173
190. Supale S, Li N, Brun T, and Maechler P. Mitochondrial dysfunction in pancreatic β cells. Trends Endocrinol Metab. (2012) 23:477–87. doi: 10.1016/j.tem.2012.06.002
191. Kaufman BA, Li C, and Soleimanpour SA. Mitochondrial regulation of β-cell function: maintaining the momentum for insulin release. Mol Aspects Med. (2015) 42:91–104. doi: 10.1016/j.mam.2015.01.004
192. Battu S, Minhas G, Mishra A, and Khan N. Amino Acid Sensing via General Control Nonderepressible-2 Kinase and Immunological Programming. Front Immunol. (2017) 8:1719. doi: 10.3389/fimmu.2017.01719
193. Zhao C, Guo H, Hou Y, Lei T, Wei D, and Zhao Y. Multiple Roles of the Stress Sensor GCN2 in Immune Cells. Int J Mol Sci. (2023) 24(5). doi: 10.3390/ijms24054285
194. Liu H, Huang L, Bradley J, Liu K, Bardhan K, Ron D, et al. GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology. Mol Cell Biol. (2014) 34:428–38. doi: 10.1128/mcb.00946-13
195. Ravishankar B, Liu H, Shinde R, Chaudhary K, Xiao W, Bradley J, et al. The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity. Proc Natl Acad Sci U S A. (2015) 112:10774–9. doi: 10.1073/pnas.1504276112
196. Cheng X, Wang P, Lyu H, Lee Y, Yoon J, and Dong H. Targeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistance. Cancer Drug Resist. (2025) 8:46. doi: 10.20517/cdr.2025.132
197. Xiong Y, Chen J, Liang W, Li K, Huang Y, Song J, et al. Blockade of the mitochondrial DNA release ameliorates hepatic ischemia-reperfusion injury through avoiding the activation of cGAS-Sting pathway. J Transl Med. (2024) 22:796. doi: 10.1186/s12967-024-05588-8
198. Li Q, Yang L, Wang K, Chen Z, Liu H, Yang X, et al. Oxidized mitochondrial DNA activates the cGAS-STING pathway in the neuronal intrinsic immune system after brain ischemia-reperfusion injury. Neurotherapeutics. (2024) 21:e00368. doi: 10.1016/j.neurot.2024.e00368
199. Luo C, Hou C, Yang D, Tan T, and Chao C. Urolithin C alleviates pancreatic β-cell dysfunction in type 1 diabetes by activating Nrf2 signaling. Nutr Diabetes. (2023) 13:24. doi: 10.1038/s41387-023-00253-3
200. Lenin R, Jha KA, Gentry J, Shrestha A, Culp EV, Vaithianathan T, et al. Tauroursodeoxycholic Acid Alleviates Endoplasmic Reticulum Stress-Mediated Visual Deficits in Diabetic tie2-TNF Transgenic Mice via TGR5 Signaling. J Ocul Pharmacol Ther. (2023) 39:159–74. doi: 10.1089/jop.2022.0117
201. Weaver FE, White E, Peek AM, Nurse CA, Austin RC, and Igdoura SA. 4-Phenylbutyric acid mitigates ER stress-induced neurodegeneration in the spinal cords of a GM2 gangliosidosis mouse model. Hum Mol Genet. (2025) 34:32–46. doi: 10.1093/hmg/ddae153
202. Delmotte P, Yap JQ, Dasgupta D, and Sieck GC. Chemical Chaperone 4-PBA Mitigates Tumor Necrosis Factor Alpha-Induced Endoplasmic Reticulum Stress in Human Airway Smooth Muscle. Int J Mol Sci. (2023). doi: 10.3390/ijms242115816
203. Jørgensen KS, Pedersen SS, Hjorth SA, Billestrup N, and Prause M. Protection of beta cells against cytokine-induced apoptosis by the gut microbial metabolite butyrate. FEBS J. (2025) 292:226–40. doi: 10.1111/febs.17334
204. Parker AM, Lees JG, Tate M, Phang RJ, Velagic A, Deo M, et al. MitoQ Protects Against Oxidative Stress-Induced Mitochondrial Dysregulation in Human Cardiomyocytes. J Mol Cell Cardiol Plus. (2025) 13:100469. doi: 10.1016/j.jmccpl.2025.100469
205. Liu B, Chen L, Gao M, Dai M, Zheng Y, Qu L, et al. A comparative study of the efficiency of mitochondria-targeted antioxidants MitoTEMPO and SKQ1 under oxidative stress. Free Radic Biol Med. (2024) 224:117–29. doi: 10.1016/j.freeradbiomed.2024.08.022
206. Rondeau JD, Lipari S, Mathieu B, Beckers C, Van de Velde JA, Mignion L, et al. Mitochondria-targeted antioxidant MitoQ radiosensitizes tumors by decreasing mitochondrial oxygen consumption. Cell Death Discovery. (2024) 10:514. doi: 10.1038/s41420-024-02277-9
207. Zaparina O, Kovner A, Petrova V, Kolosova N, Mordvinov V, and Pakharukova M. Plastoquinone-Derivative SkQ1 Improved the Biliary Intraepithelial Neoplasia during Liver Fluke Infection. Curr Issues Mol Biol. (2024) 46:1593–606. doi: 10.3390/cimb46020103
208. Sun J, Jin S, and Wang Z. MitoQ alleviates mitochondria damage in sepsis-acute lung injury in a citrate synthase dependent manner. Inflammation Res. (2025) 74:92. doi: 10.1007/s00011-025-02055-y
209. Zolfaghari A, Omidi A, and Soodi M. Mitochondria-targeted antioxidant skq1 reverses functional impairment and histopathological insults in a chronic animal model of multiple sclerosis. Metab Brain Dis. (2025) 40:249. doi: 10.1007/s11011-025-01676-w
210. Jabůrek M, Klöppel E, Průchová P, Mozheitova O, Tauber J, Engstová H, et al. Mitochondria to plasma membrane redox signaling is essential for fatty acid β-oxidation-driven insulin secretion. Redox Biol. (2024) 75:103283. doi: 10.1016/j.redox.2024.103283
211. Kumar P, Kinger S, Dubey AR, Jagtap YA, Choudhary A, Prasad A, et al. Trehalose Promotes Clearance of Proteotoxic Aggregation of Neurodegenerative Disease-Associated Aberrant Proteins. Mol Neurobiol. (2024) 61:4055–73. doi: 10.1007/s12035-023-03824-8
212. Díaz-Osorio Y, Gimeno-Agud H, Mari-Vico R, Illescas S, Ramos JM, Darling A, et al. Spermidine Recovers the Autophagy Defects Underlying the Pathophysiology of Cell Trafficking Disorders. J Inherit Metab Dis. (2025) 48:e12841. doi: 10.1002/jimd.12841
213. Xi H, Shan W, Li M, Wang Z, and Li Y. Trehalose attenuates testicular aging by activating autophagy and improving mitochondrial quality. Andrology. (2025) 13:911–20. doi: 10.1111/andr.13746
214. Sodré FMC, Bissenova S, Bruggeman Y, Tilvawala R, Cook DP, Berthault C, et al. Peptidylarginine Deiminase Inhibition Prevents Diabetes Development in NOD Mice. Diabetes. (2021) 70:516–28. doi: 10.2337/db20-0421
215. Marre ML, McGinty JW, Chow IT, DeNicola ME, Beck NW, Kent SC, et al. Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4(+) T Cells in Patients With Type 1 Diabetes. Diabetes. (2018) 67:1356–68. doi: 10.2337/db17-1166
216. Delong T, Wiles TA, Baker RL, Bradley B, Barbour G, Reisdorph R, et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science. (2016) 351:711–4. doi: 10.1126/science.aad2791
217. Yang ML, Horstman S, Gee R, Guyer P, Lam TT, Kanyo J, et al. Citrullination of glucokinase is linked to autoimmune diabetes. Nat Commun. (2022) 13:1870. doi: 10.1038/s41467-022-29512-0
218. Raposo B, Merky P, Lundqvist C, Yamada H, Urbonaviciute V, Niaudet C, et al. T cells specific for post-translational modifications escape intrathymic tolerance induction. Nat Commun. (2018) 9:353. doi: 10.1038/s41467-017-02763-y
219. Buitinga M, Callebaut A, Marques Câmara Sodré F, Crèvecoeur I, Blahnik-Fagan G, Yang ML, et al. Inflammation-Induced Citrullinated Glucose-Regulated Protein 78 Elicits Immune Responses in Human Type 1 Diabetes. Diabetes. (2018) 67:2337–48. doi: 10.2337/db18-0295
220. Marré ML, Profozich JL, Coneybeer JT, Geng X, Bertera S, Ford MJ, et al. Inherent ER stress in pancreatic islet β cells causes self-recognition by autoreactive T cells in type 1 diabetes. J Autoimmun. (2016) 72:33–46. doi: 10.1016/j.jaut.2016.04.009
221. Azoury ME, Samassa F, Buitinga M, Nigi L, Brusco N, Callebaut A, et al. CD8(+) T Cells Variably Recognize Native Versus Citrullinated GRP78 Epitopes in Type 1 Diabetes. Diabetes. (2021) 70:2879–91. doi: 10.2337/db21-0259
222. Mitchell JS, Spanier JA, Dwyer AJ, Knutson TP, Alkhatib MH, Qian G, et al. CD4(+) T cells reactive to a hybrid peptide from insulin-chromogranin A adopt a distinct effector fate and are pathogenic in autoimmune diabetes. Immunity. (2024) 57:2399–415.e8. doi: 10.1016/j.immuni.2024.07.024
223. Lewallen DM, Bicker KL, Madoux F, Chase P, Anguish L, Coonrod S, et al. A FluoPol-ABPP PAD2 high-throughput screen identifies the first calcium site inhibitor targeting the PADs. ACS Chem Biol. (2014) 9:913–21. doi: 10.1021/cb400841k
224. Shen Y, You Q, Wu Y, and Wu J. Inhibition of PAD4-mediated NET formation by cl-amidine prevents diabetes development in nonobese diabetic mice. Eur J Pharmacol. (2022) 916:174623. doi: 10.1016/j.ejphar.2021.174623
225. Li B, Ming H, Qin S, Nice EC, Dong J, Du Z, et al. Redox regulation: mechanisms, biology and therapeutic targets in diseases. Signal Transduct Target Ther. (2025) 10:72. doi: 10.1038/s41392-024-02095-6
226. Pei Y, Wan S, Qi J, Xi X, Zhu Y, An P, et al. Mitochondrial Transport Proteins in Cardiovascular Diseases: Metabolic Gatekeepers, Pathogenic Mediators and Therapeutic Targets. Int J Mol Sci. (2025) 26. doi: 10.3390/ijms26178475
227. Surugiu R, Iancu MA, Vintilescu ȘB, Stepan MD, Burdusel D, Genunche-Dumitrescu AV, et al. Molecular Mechanisms of Healthy Aging: The Role of Caloric Restriction, Intermittent Fasting, Mediterranean Diet, and Ketogenic Diet-A Scoping Review. Nutrients. (2024) 16. doi: 10.3390/nu16172878
228. Bellanti F, Coda ARD, Trecca MI, Lo Buglio A, Serviddio G, and Vendemiale G. Redox Imbalance in Inflammation: The Interplay of Oxidative and Reductive Stress. Antioxidants (Basel). (2025) 14. doi: 10.3390/antiox14060656
229. Shi C, Wen Z, Yang Y, Shi L, and Liu D. NAD+ metabolism and therapeutic strategies in cardiovascular diseases. Atheroscler Plus. (2024) 57:1–12. doi: 10.1016/j.athplu.2024.06.001
230. Hong H, Wang Y, Menard M, Buckley JA, Zhou L, Volpicelli-Daley L, et al. Suppression of the JAK/STAT pathway inhibits neuroinflammation in the line 61-PFF mouse model of Parkinson's disease. J Neuroinflammation. (2024) 21:216. doi: 10.1186/s12974-024-03210-8
231. Xu R, He X, Xu J, Yu G, and Wu Y. Immunometabolism: signaling pathways, homeostasis, and therapeutic targets. MedComm (2020). (2024) 5:e789. doi: 10.1002/mco2.789
232. Jansen D, Nikolic T, den Hollander NHM, Zwaginga JJ, and Roep BO. Bridging the Gap Between Tolerogenic Dendritic Cells In Vitro and In Vivo: Analysis of Siglec Genes and Pathways Associated with Immune Modulation and Evasion. Genes (Basel). (2024). doi: 10.3390/genes15111427
233. You H, Shin U, Kwon DH, Hwang J, Lee GY, and Han SN. The effects of in vitro vitamin D treatment on glycolytic reprogramming of bone marrow-derived dendritic cells from Ldlr knock-out mouse. Biochim Biophys Acta Mol Basis Dis. (2024) 1870:167436. doi: 10.1016/j.bbadis.2024.167436
234. Applegate CC, Kang Y, Deng H, Chen D, Gonzalez Medina NY, Cui Y, et al. Nanomedicine targeting PPAR in adipose tissue macrophages improves lipid metabolism and obesity-induced metabolic dysfunction. Sci Adv. (2025) 11:eads3731. doi: 10.1126/sciadv.ads3731
235. Lou YL, Xie DL, Huang XH, Zheng MM, Chen N, and Xu JR. The role of MNK1-mTORC1 pathway in modulating macrophage responses to Vibrio vulnificus infection. Microbiol Spectr. (2024) 12:e0334023. doi: 10.1128/spectrum.03340-23
236. Ball AB, Jones AE, Nguyễn KB, Rios A, Marx N, Hsieh WY, et al. Pro-inflammatory macrophage activation does not require inhibition of oxidative phosphorylation. EMBO Rep. (2025) 26:982–1002. doi: 10.1038/s44319-024-00351-y
237. Wixler V, Boergeling Y, Leite Dantas R, Varga G, and Ludwig S. Conversion of dendritic cells into tolerogenic or inflammatory cells depends on the activation threshold and kinetics of the mTOR signaling pathway. Cell Commun Signal. (2024) 22:281. doi: 10.1186/s12964-024-01655-1
238. Lv D, Jiang H, Yang X, Li Y, Niu W, and Zhang D. Advances in understanding of dendritic cell in the pathogenesis of acute kidney injury. Front Immunol. (2024) 15:1294807. doi: 10.3389/fimmu.2024.1294807
239. Rius-Bonet J, Macip S, Massip-Salcedo M, and Closa D. Effects of Fasting on THP1 Macrophage Metabolism and Inflammatory Profile. Int J Mol Sci. (2024) 25. doi: 10.3390/ijms25169029
240. Ataman M, Mittal N, Tintignac L, Schmidt A, Ham DJ, González A, et al. Calorie restriction and rapamycin distinctly mitigate aging-associated protein phosphorylation changes in mouse muscles. Commun Biol. (2024) 7:974. doi: 10.1038/s42003-024-06679-4
241. Freemantle JB and Hardie DG. AMPK promotes lysosomal and mitochondrial biogenesis via folliculin:FNIP1. Life Metab. (2023) 2:load027. doi: 10.1093/lifemeta/load027
242. Kazyken D, Dame SG, Wang C, Wadley M, and Fingar DC. Unexpected roles for AMPK in the suppression of autophagy and the reactivation of MTORC1 signaling during prolonged amino acid deprivation. Autophagy. (2024) 20:2017–40. doi: 10.1080/15548627.2024.2355074
243. St Paul M, Saibil SD, Kates M, Han S, Lien SC, Laister RC, et al. Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy. Cell Rep Med. (2024) 5:101465. doi: 10.1016/j.xcrm.2024.101465
244. Hou Y, Wei D, Zhang Z, Lei T, Li S, Bao J, et al. Downregulation of nutrition sensor GCN2 in macrophages contributes to poor wound healing in diabetes. Cell Rep. (2024) 43:113658. doi: 10.1016/j.celrep.2023.113658
245. Akca U, Zhang Y, Yasui N, Hensley C, Sorace A, Larimer BM, et al. PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model. J Nucl Med. (2025). doi: 10.2967/jnumed.125.270466
246. Asada N, Ginsberg P, Paust HJ, Song N, Riedel JH, Turner JE, et al. The integrated stress response pathway controls cytokine production in tissue-resident memory CD4(+) T cells. Nat Immunol. (2025) 26:557–66. doi: 10.1038/s41590-025-02105-x
247. Zhu J, Wei J, Lin Y, Tang Y, Su Z, Li L, et al. Inhibition of IL-17 signaling in macrophages underlies the anti-arthritic effects of halofuginone hydrobromide: Network pharmacology, molecular docking, and experimental validation. BMC Complement Med Ther. (2024) 24:105. doi: 10.1186/s12906-024-04397-2
248. Wang X, Dai C, Cheng W, Wang J, Cui X, Pan G, et al. Repressing cytokine storm-like response in macrophages by targeting the eIF2α-integrated stress response pathway. Int Immunopharmacol. (2025) 147:113965. doi: 10.1016/j.intimp.2024.113965
249. Rueda GH, Causada-Calo N, Borojevic R, Nardelli A, Pinto-Sanchez MI, Constante M, et al. Oral tryptophan activates duodenal aryl hydrocarbon receptor in healthy subjects: a crossover randomized controlled trial. Am J Physiol Gastrointest Liver Physiol. (2024) 326:G687–g96. doi: 10.1152/ajpgi.00306.2023
250. Stayer K, Pathan S, Biswas A, Li H, Zhu Y, Lam FW, et al. Exogenous arginine differentially regulates inflammatory cytokine and inducible nitric oxide synthase expression in macrophages. Immunohorizons. (2025) 9. doi: 10.1093/immhor/vlaf028
251. Fernando V, Zheng X, Sharma V, Sweef O, Choi ES, and Furuta S. Reprogramming of breast tumor-associated macrophages with modulation of arginine metabolism. Life Sci Alliance. (2024). doi: 10.26508/lsa.202302339
252. Moreno-Lanceta A, Medrano-Bosch M, Simón-Codina B, Barber-González M, Jiménez W, and Melgar-Lesmes P. PPAR-γ Agonist GW1929 Targeted to Macrophages with Dendrimer-Graphene Nanostars Reduces Liver Fibrosis and Inflammation. Pharmaceutics. (2023). doi: 10.3390/pharmaceutics15051452
253. Zuo S, Wang Y, Bao H, Zhang Z, Yang N, Jia M, et al. Lipid synthesis, triggered by PPARγ T166 dephosphorylation, sustains reparative function of macrophages during tissue repair. Nat Commun. (2024) 15:7269. doi: 10.1038/s41467-024-51736-5
254. Cetti F, Ossoli A, Garavaglia C, Da Dalt L, Norata GD, and Gomaraschi M. PPAR-mediated reduction of lipid accumulation in hepatocytes involves the autophagy-lysosome-mitochondrion axis. Ann Med. (2025) 57:2497112. doi: 10.1080/07853890.2025.2497112
255. Noori M, Azimirad M, Ghorbaninejad M, Meyfour A, Zali MR, and Yadegar A. PPAR-γ agonist mitigates intestinal barrier dysfunction and inflammation induced by Clostridioides difficile SlpA in vitro. Sci Rep. (2024) 14:32087. doi: 10.1038/s41598-024-83815-4
256. Wang Y, Wang M, Jia X, Tang Y, Wang J, Zhang W, et al. PPAR-γ Inhibits Chronic Apical Periodontitis by Facilitating Macrophage Efferocytosis. Int J Mol Sci. (2025) 26. doi: 10.3390/ijms262010157
257. Zhang Y, Wu F, Li Y, Liu J, Zhu L, Zhang M, et al. SREBF1 mediates immunoparalysis of dendritic cells in sepsis by regulating lipid metabolism and endoplasmic reticulum stress. Cell Commun Signal. (2025) 23:286. doi: 10.1186/s12964-025-02295-9
258. Galderisi A. Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us. Pediatr Endocrinol Diabetes Metab. (2023) 29:1–3. doi: 10.5114/pedm.2023.126360
259. Galderisi A, Carr ALJ, Martino M, Taylor P, Senior P, and Dayan C. Quantifying beta cell function in the preclinical stages of type 1 diabetes. Diabetologia. (2023) 66:2189–99. doi: 10.1007/s00125-023-06011-5
260. Sims EK, Geyer SM, Long SA, and Herold KC. High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment. Diabetologia. (2023) 66:2283–91. doi: 10.1007/s00125-023-06003-5
261. Al-Mulla F, Alhomaidah D, Abu-Farha M, Hasan A, Al-Khairi I, Nizam R, et al. Early autoantibody screening for type 1 diabetes: a Kuwaiti perspective on the advantages of multiplexing chemiluminescent assays. Front Immunol. (2023) 14:1273476. doi: 10.3389/fimmu.2023.1273476
262. Batir-Marin D, Ștefan CS, Boev M, Gurău G, Popa GV, Matei MN, et al. A Multidisciplinary Approach of Type 1 Diabetes: The Intersection of Technology, Immunotherapy, and Personalized Medicine. J Clin Med. (2025) 14. doi: 10.3390/jcm14072144
263. Gordon JW, Chen HY, Nickles T, Lee PM, Bok R, Ohliger MA, et al. Hyperpolarized (13)C Metabolic MRI of Patients with Pancreatic Ductal Adenocarcinoma. J Magn Reson Imaging. (2024) 60:741–9. doi: 10.1002/jmri.29162
264. Prasuhn J, Schiefen T, Güber T, Henkel J, Uter J, Steinhardt J, et al. Levodopa Impairs the Energy Metabolism of the Basal Ganglia In Vivo. Ann Neurol. (2024) 95:849–57. doi: 10.1002/ana.26884
265. Nunes JB, Ijsselsteijn ME, Abdelaal T, Ursem R, van der Ploeg M, Giera M, et al. Integration of mass cytometry and mass spectrometry imaging for spatially resolved single-cell metabolic profiling. Nat Methods. (2024) 21:1796–800. doi: 10.1038/s41592-024-02392-6
266. Weng C, Gu A, Zhang S, Lu L, Ke L, Gao P, et al. Single cell multiomic analysis reveals diabetes-associated β-cell heterogeneity driven by HNF1A. Nat Commun. (2023) 14:5400. doi: 10.1038/s41467-023-41228-3
267. Kar R, Chattopadhyay S, Sharma A, Sharma K, Sinha S, Arimbasseri GA, et al. Single-cell transcriptomic and T cell antigen receptor analysis of human cytomegalovirus (hCMV)-specific memory T cells reveals effectors and pre-effectors of CD8(+)- and CD4(+)-cytotoxic T cells. Immunology. (2024) 172:420–39. doi: 10.1111/imm.13783
268. Ladakis DC, Pedrini E, Reyes-Mantilla MI, Sanjayan M, Smith MD, Fitzgerald KC, et al. Metabolomics of Multiple Sclerosis Lesions Demonstrates Lipid Changes Linked to Alterations in Transcriptomics-Based Cellular Profiles. Neurol Neuroimmunol Neuroinflamm. (2024) 11:e200219. doi: 10.1212/nxi.0000000000200219
269. Prateeksha P, Howlader MSI, Hansda S, Naidu P, Das M, Abo-Aziza F, et al. Secretome of Dental Pulp-Derived Stem Cells Reduces Inflammation and Proliferation of Glioblastoma Cells by Deactivating Mapk-Akt Pathway. Dis Res. (2023) 3:74–86. doi: 10.54457/dr.202302006
270. Chia ML, Bulat F, Gaunt A, Ros S, Wright AJ, Sawle A, et al. Metabolic imaging distinguishes ovarian cancer subtypes and detects their early and variable responses to treatment. Oncogene. (2025) 44:563–74. doi: 10.1038/s41388-024-03231-w
271. Melamed JR, Yerneni SS, Arral ML, LoPresti ST, Chaudhary N, Sehrawat A, et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer. Sci Adv. (2023) 9:eade1444. doi: 10.1126/sciadv.ade1444
272. Primavera R, Wang J, Buchwald P, Ganguly A, Patel S, Bettencourt L, et al. Controlled Nutrient Delivery to Pancreatic Islets Using Polydopamine-Coated Mesoporous Silica Nanoparticles. Nano Lett. (2025) 25:939–50. doi: 10.1021/acs.nanolett.4c03613
273. Krishnan SR, Liu C, Bochenek MA, Bose S, Khatib N, Walters B, et al. A wireless, battery-free device enables oxygen generation and immune protection of therapeutic xenotransplants in vivo. Proc Natl Acad Sci U S A. (2023) 120:e2311707120. doi: 10.1073/pnas.2311707120
274. Liu M, Deng H, Liu C, Wang L, Liao Z, Li D, et al. Islet transplantation in immunomodulatory nanoparticle-remodeled spleens. Sci Transl Med. (2025) 17:eadj9615. doi: 10.1126/scitranslmed.adj9615
275. Couch CA, Piccinini F, Fowler LA, Garvey WT, and Gower BA. Proinsulin-to-C-Peptide Ratio as a Marker of β-Cell Function in African American and European American Adults. Diabetes Care. (2023) 46:2129–36. doi: 10.2337/dc22-1763
276. Miya A, Nakamura A, Nomoto H, Kameda H, and Atsumi T. Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes. Endocr J. (2024) 71:403–8. doi: 10.1507/endocrj.EJ23-0525
277. Alemán-Contreras R, Gómez-Díaz RA, Noyola-García ME, Mondragón-González R, Wacher N, and Ferreira-Hermosillo A. Utility of Fasting C-Peptide for the Diagnostic Differentiation of Patients with Type 1, Type 2 Diabetes, MODY, and LADA. Life (Basel). (2024) 14. doi: 10.3390/life14050550
278. Al Zaidi M, Marggraf V, Repges E, Nickenig G, Skowasch D, Aksoy A, et al. Relevance of serum levels of the endoplasmic reticulum stress protein GRP78 (glucose-regulated protein 78 kDa) as biomarker in pulmonary diseases. Cell Stress Chaperones. (2023) 28:333–41. doi: 10.1007/s12192-023-01341-0
279. Clemen R, Dethloff W, Berner J, Schulan P, Martinet A, Weltmann KD, et al. Insulin oxidation and oxidative modifications alter glucose uptake, cell metabolism, and inflammatory secretion profiles. Redox Biol. (2024) 77:103372. doi: 10.1016/j.redox.2024.103372
280. Yuzefovych LV, Pastukh VM, Mulekar MS, Ledbetter K, Richards WO, and Rachek LI. Effect of Bariatric Surgery on Plasma Cell-Free Mitochondrial DNA, Insulin Sensitivity and Metabolic Changes in Obese Patients. Biomedicines. (2023) 11. doi: 10.3390/biomedicines11092514
281. Mengozzi A, Armenia S, De Biase N, Punta LD, Cappelli F, Duranti E, et al. Circulating mitochondrial DNA signature in cardiometabolic patients. Cardiovasc Diabetol. (2025) 24:106. doi: 10.1186/s12933-025-02656-1
282. Keshavan N, Mhaldien L, Gilmour K, and Rahman S. Interferon Stimulated Gene Expression Is a Biomarker for Primary Mitochondrial Disease. Ann Neurol. (2024) 96:1185–200. doi: 10.1002/ana.27081
283. Warren EB, Gordon-Lipkin EM, Cheung F, Chen J, Mukherjee A, Apps R, et al. Inflammatory and interferon gene expression signatures in patients with mitochondrial disease. J Transl Med. (2023) 21:331. doi: 10.1186/s12967-023-04180-w
284. Trumpff C, Shire D, Lee S, Stanko K, Park A, Wilson A, et al. Effects of acute psychological stress on blood cell-free mitochondrial DNA (cf-mtDNA): A crossover experimental study. Psychoneuroendocrinology. (2025) 182:107644. doi: 10.1016/j.psyneuen.2025.107644
285. Adeshara K, Di Marco E, Bordino M, Gordin D, Bernardi L, Cooper ME, et al. Altered oxidant and antioxidant levels are associated with vascular stiffness and diabetic kidney disease in type 1 diabetes after exposure to acute and chronic hyperglycemia. Cardiovasc Diabetol. (2024) 23:350. doi: 10.1186/s12933-024-02427-4
286. Leacy E, Batten I, Sanelli L, McElheron M, Brady G, Little MA, et al. Optimal LC-MS metabolomic profiling reveals emergent changes to monocyte metabolism in response to lipopolysaccharide. Front Immunol. (2023) 14:1116760. doi: 10.3389/fimmu.2023.1116760
287. Chen HJ, Sévin DC, Griffith GR, Vappiani J, Booty LM, van Roomen C, et al. Integrated metabolic-transcriptomic network identifies immunometabolic modulations in human macrophages. Cell Rep. (2024) 43:114741. doi: 10.1016/j.celrep.2024.114741
288. Hu T, Liu CH, Lei M, Zeng Q, Li L, Tang H, et al. Metabolic regulation of the immune system in health and diseases: mechanisms and interventions. Signal Transduct Target Ther. (2024) 9:268. doi: 10.1038/s41392-024-01954-6
289. Povo-Retana A, Landauro-Vera R, Fariñas M, Sánchez-García S, Alvarez-Lucena C, Marin S, et al. Defining the metabolic signatures associated with human macrophage polarisation. Biochem Soc Trans. (2023) 51:1429–36. doi: 10.1042/bst20220504
290. De Leo A, Ugolini A, Yu X, Scirocchi F, Scocozza D, Peixoto B, et al. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma. Immunity. (2024) 57:1105–23.e8. doi: 10.1016/j.immuni.2024.04.006
291. Wu Y, Zhao M, Gong N, Zhang F, Chen W, and Liu Y. Immunometabolomics provides a new perspective for studying systemic lupus erythematosus. Int Immunopharmacol. (2023) 118:109946. doi: 10.1016/j.intimp.2023.109946
292. Iborra Pernichi M, Ruiz García J, and Martínez-Martín N. Quantification of Intracellular ATP Content in Ex Vivo GC B Cells. Methods Mol Biol. (2023) 2675:109–15. doi: 10.1007/978-1-0716-3247-5_9
293. Campia G, Beltrán-Visiedo M, Soler-Agesta R, Sato A, Bloy N, Zhao L, et al. Flow cytometry-assisted analysis of phenotypic maturation markers on an immortalized dendritic cell line. Methods Cell Biol. (2024) 189:153–68. doi: 10.1016/bs.mcb.2024.05.008
294. Harjunpää H, Somermäki R, Saldo Rubio G, Fusciello M, Feola S, Faisal I, et al. Loss of β2-integrin function results in metabolic reprogramming of dendritic cells, leading to increased dendritic cell functionality and anti-tumor responses. Oncoimmunology. (2024) 13:2369373. doi: 10.1080/2162402x.2024.2369373
295. Hu T, Allam M, Cai S, Henderson W, Yueh B, Garipcan A, et al. Single-cell spatial metabolomics with cell-type specific protein profiling for tissue systems biology. Nat Commun. (2023) 14:8260. doi: 10.1038/s41467-023-43917-5
296. Melkonian AL, Cheung MD, Erman EN, Moore KH, Lever JMP, Jiang Y, et al. Single-cell RNA sequencing and spatial transcriptomics reveal unique subpopulations of infiltrating macrophages and dendritic cells following AKI. Am J Physiol Renal Physiol. (2025) 328:F907–f20. doi: 10.1152/ajprenal.00059.2025
297. Huber F, Arnaud M, Stevenson BJ, Michaux J, Benedetti F, Thevenet J, et al. A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat Biotechnol. (2025) 43:1360–72. doi: 10.1038/s41587-024-02420-y
298. Rosario SR, Long MD, Chilakapati S, Gomez EC, Battaglia S, Singh PK, et al. Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer. Nat Commun. (2024) 15:10609. doi: 10.1038/s41467-024-54565-8
299. Mittal R, Weiss MB, Rendon A, Shafazand S, Lemos JRN, and Hirani K. Harnessing Machine Learning, a Subset of Artificial Intelligence, for Early Detection and Diagnosis of Type 1 Diabetes: A Systematic Review. Int J Mol Sci. (2025) 26(9). doi: 10.3390/ijms26093935
300. Mitchell AM, Baschal EE, McDaniel KA, Fleury T, Choi H, Pyle L, et al. Tracking DNA-based antigen-specific T cell receptors during progression to type 1 diabetes. Sci Adv. (2023) 9:eadj6975. doi: 10.1126/sciadv.adj6975
301. Urrutia I, Martinez R, Calvo B, Marcelo I, Saso-Jimenez L, Martinez de Lapiscina I, et al. Risk for progression to type 1 diabetes in first-degree relatives under 50 years of age. Front Endocrinol (Lausanne). (2024) 15:1411686. doi: 10.3389/fendo.2024.1411686
302. Pant T, Lin CW, Bedrat A, Jia S, Roethle MF, Truchan NA, et al. Monocytes in type 1 diabetes families exhibit high cytolytic activity and subset abundances that correlate with clinical progression. Sci Adv. (2024) 10:eadn2136. doi: 10.1126/sciadv.adn2136
303. Dekkers MC, Lambooij JM, Pu X, Fagundes RR, Enciso-Martinez A, Kats K, et al. Extracellular vesicles derived from stressed beta cells mediate monocyte activation and contribute to islet inflammation. Front Immunol. (2024) 15:1393248. doi: 10.3389/fimmu.2024.1393248
304. Sag D, Carling D, Stout RD, and Suttles J. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol. (2008) 181:8633–41. doi: 10.4049/jimmunol.181.12.8633
305. Yang L, Han Y, Zhang T, Dong X, Ge J, Roy A, et al. Human vascularized macrophage-islet organoids to model immune-mediated pancreatic β cell pyroptosis upon viral infection. Cell Stem Cell. (2024) 31:1612–29.e8. doi: 10.1016/j.stem.2024.08.007
Keywords: immune tolerance, immunometabolism, major histocompatibility complex class I, metabolic reprogramming, neoepitopes, redox signaling, type 1 diabetes, β-cell stress
Citation: Mittal R, Goldmann R, Mittal M, Chaudhary N, Ravindra V and Hirani K (2026) Neoepitopes at the crossroads of immunometabolism: metabolic remodeling of antigen presentation in type 1 diabetes. Front. Immunol. 17:1744422. doi: 10.3389/fimmu.2026.1744422
Received: 11 November 2025; Accepted: 02 January 2026; Revised: 15 December 2025;
Published: 30 January 2026.
Edited by:
Eddie A. James, Benaroya Research Institute, United StatesReviewed by:
Mark Mamula, Yale University, United StatesXiaoxiao Wan, Washington University School of Medicine, United States
Copyright © 2026 Mittal, Goldmann, Mittal, Chaudhary, Ravindra and Hirani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rahul Mittal, ci5taXR0YWwxMUBtZWQubWlhbWkuZWR1; Khemraj Hirani, a2hpcmFuaUBtZWQubWlhbWkuZWR1